<SEC-DOCUMENT>0000939767-20-000034.txt : 20200225
<SEC-HEADER>0000939767-20-000034.hdr.sgml : 20200225
<ACCEPTANCE-DATETIME>20200225160937
ACCESSION NUMBER:		0000939767-20-000034
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20200225
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200225
DATE AS OF CHANGE:		20200225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0103

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		20650690

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>exel8-kq42019earningsr.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:0244eccc0efe4124930360393b981fb3,x:e5e53d19203d4f14890f1327aab3fcc0-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:exel="http://www.exelicis.com/20200225" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="D2020Q1FilingDateFeb25" name="dei:AmendmentFlag" id="Fact-7B9A8A67D8965AA3B7AF0AB2FDB0B173-wk-Fact-7B9A8A67D8965AA3B7AF0AB2FDB0B173" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="D2020Q1FilingDateFeb25" name="dei:EntityCentralIndexKey" id="Fact-350BBFF49FE45D429976426DFD564A84-wk-Fact-350BBFF49FE45D429976426DFD564A84">0000939767</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="exel-20200225.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="D2020Q1FilingDateFeb25">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-02-25</xbrli:startDate>
			<xbrli:endDate>2020-02-25</xbrli:endDate>
		</xbrli:period>
	</xbrli:context></ix:resources></ix:header></div><div><a id="sD9069D1C3618595D9843E7903DF12073"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:16pt;"><span style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;font-size:16pt;"><span style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Calibri,sans-serif;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</span><span style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:266px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:133px;"></td><td style="width:133px;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:right;font-size:16pt;"><span style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">FORM </span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:left;font-size:16pt;"><span style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;"><span><ix:nonNumeric id="d41425420e96-wk-Fact-489A86B29C7D5C4D9885A13070C6BD7C" name="dei:DocumentType" contextRef="D2020Q1FilingDateFeb25">8-K</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CURRENT REPORT </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 13 OR 15(d) OF THE </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Date of Report (Date of earliest event reported): </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d41425420e110-wk-Fact-D29E5DFF7F7D591881758F515B1606B3" name="dei:DocumentPeriodEndDate" contextRef="D2020Q1FilingDateFeb25" format="ixt:datemonthdayyearen">February 25, 2020</ix:nonNumeric></span></span></span></div><div style="line-height:120%;text-align:center;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:267px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:266px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;"><img src="exellogo18q3a10.jpg" alt="exellogo18q3a10.jpg" style="height:49px;width:148px;"></img></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;font-size:16pt;"><span style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;"><span><ix:nonNumeric id="d41425420e129-wk-Fact-13838CE6DFF65CC492941BD05CFB4055" name="dei:EntityRegistrantName" contextRef="D2020Q1FilingDateFeb25">EXELIXIS, INC.</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">(Exact name of registrant as specified in its charter)</span></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d41425420e153-wk-Fact-C070CDB2083E59F59954A312C8D78EBB" name="dei:EntityIncorporationStateCountryCode" contextRef="D2020Q1FilingDateFeb25" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d41425420e158-wk-Fact-3B3DE49764055A11BF94785A1942F3E1" name="dei:EntityFileNumber" contextRef="D2020Q1FilingDateFeb25">000-30235</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d41425420e163-wk-Fact-08496EF451965B6BA76E7CCBC1E1AA10" name="dei:EntityTaxIdentificationNumber" contextRef="D2020Q1FilingDateFeb25">04-3257395</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;text-indent:2px;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">(State or Other Jurisdiction of Incorporation)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;text-indent:2px;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">(Commission File Number)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;text-indent:2px;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">(IRS Employer Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Calibri,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d41425420e185-wk-Fact-41CB20C1D5375A6D80777630DBA4D259" name="dei:EntityAddressAddressLine1" contextRef="D2020Q1FilingDateFeb25"><span style="font-family:Calibri,sans-serif;font-weight:bold;">1851 Harbor Bay Parkway</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d41425420e191-wk-Fact-683D139325D35DD5A3466446B3962EEB" name="dei:EntityAddressCityOrTown" contextRef="D2020Q1FilingDateFeb25"><span style="font-family:Calibri,sans-serif;font-weight:bold;">Alameda</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d41425420e196-wk-Fact-18F1E2566E4759D2AAE6CE184BC1ACF6" name="dei:EntityAddressStateOrProvince" contextRef="D2020Q1FilingDateFeb25" format="ixt-sec:stateprovnameen"><span style="font-family:Calibri,sans-serif;font-weight:bold;">California</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d41425420e201-wk-Fact-6C42445B3A4E5F319B6972E519DD65B5" name="dei:EntityAddressPostalZipCode" contextRef="D2020Q1FilingDateFeb25"><span style="font-family:Calibri,sans-serif;font-weight:bold;">94502</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">(Address of principal executive offices) (Zip Code)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d41425420e214-wk-Fact-90A806F7734E5497B541D216472F0B42" name="dei:CityAreaCode" contextRef="D2020Q1FilingDateFeb25"><span style="font-family:Calibri,sans-serif;font-weight:bold;">650</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">) </span><span><ix:nonNumeric id="d41425420e219-wk-Fact-DC393A97DCA9514B8B38B8724096377B" name="dei:LocalPhoneNumber" contextRef="D2020Q1FilingDateFeb25"><span style="font-family:Calibri,sans-serif;font-weight:bold;">837-7000</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">(Registrant&#8217;s telephone number, including area code) </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><span><ix:nonNumeric id="d41425420e231-wk-Fact-0415EBE197885348BCAD134A532E744B" name="dei:WrittenCommunications" contextRef="D2020Q1FilingDateFeb25" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><span><ix:nonNumeric id="d41425420e239-wk-Fact-095D4C1D8DD85073935F4B37A7FE8DAB" name="dei:SolicitingMaterial" contextRef="D2020Q1FilingDateFeb25" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><span><ix:nonNumeric id="d41425420e247-wk-Fact-CFBA24DE466F52DDB4A67DA71D8272C9" name="dei:PreCommencementTenderOffer" contextRef="D2020Q1FilingDateFeb25" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><span><ix:nonNumeric id="d41425420e256-wk-Fact-911BCF8B9EB454099B4EBCF71784ABBF" name="dei:PreCommencementIssuerTenderOffer" contextRef="D2020Q1FilingDateFeb25" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.62698412698413%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:39%;"></td><td style="width:21%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d41425420e298-wk-Fact-109F18A8A2E059EABE57899D254F1687" name="dei:Security12bTitle" contextRef="D2020Q1FilingDateFeb25">Common Stock $.001 Par Value per Share</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d41425420e303-wk-Fact-9D247C10CBB958F990AA22A36FC540CB" name="dei:TradingSymbol" contextRef="D2020Q1FilingDateFeb25">EXEL</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d41425420e308-wk-Fact-C016873BF1AC5245AEB6D3228CEF854D" name="dei:SecurityExchangeName" contextRef="D2020Q1FilingDateFeb25" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company</span><span style="font-family:inherit;font-size:10pt;"> </span><span><ix:nonNumeric id="d41425420e317-wk-Fact-8FFF01B4536950E58A81C191922A5331" name="dei:EntityEmergingGrowthCompany" contextRef="D2020Q1FilingDateFeb25" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="s9D21113D682851728EE8135C6484F574"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Item 2.02.  Results of Operations and Financial Condition.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">On </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, Exelixis, Inc. (&#8220;Exelixis&#8221;) issued a press release announcing its financial results for the quarter and full year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">January&#160;3, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The information in this report, including the exhibit hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Exelixis, whether made before or after the date hereof, regardless of any general incorporation language in such filing. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Item 9.01.  Financial Statements and Exhibits.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d) &#160;&#160;&#160;&#160;Exhibits.</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:58%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Exhibit Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Exhibit Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">99.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20191231exhibit991.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Press Release issued February 25, 2020.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">101.INS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">XBRL Instance Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The XBRL instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">101.SCH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inline XBRL Taxonomy Extension Schema Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">101.CAL</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">101.DEF</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">101.LAB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">101.PRE</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">104</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cover Page Interactive Data File</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Formatted as Inline XBRL and contained in Exhibit 101.</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="s045F7C4365F55E4EA0D259D7739849B1"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SIGNATURES </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:71.42857142857143%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="4"></td></tr><tr><td style="width:28%;"></td><td style="width:8%;"></td><td style="width:8%;"></td><td style="width:56%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">E</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">XELIXIS, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">I</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">NC.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;25, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">/s/ J</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">EFFREY</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. H</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">ESSEKIEL</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Jeffrey J. Hessekiel</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and General Counsel</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exel20191231exhibit991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s342B8489085850CC9546E47A1458D6FC"></a></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.90522243713733%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:29%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:768px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#ff0000;font-weight:bold;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;"><img src="exellogo18q3a10.jpg" alt="exellogo18q3a10.jpg" style="height:60px;width:177px;"></div><div style="line-height:120%;padding-top:0px;text-align:right;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;font-weight:bold;">Contacts:</font></div><div style="line-height:120%;padding-top:0px;text-align:right;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;">Chris Senner</font></div><div style="line-height:120%;padding-top:0px;text-align:right;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;">Chief Financial Officer</font></div><div style="line-height:120%;padding-top:0px;text-align:right;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;">Exelixis, Inc.</font></div><div style="line-height:120%;padding-top:0px;text-align:right;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;">650-837-7240</font></div><div style="line-height:120%;padding-top:0px;text-align:right;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#006ba6;font-style:italic;text-decoration:underline;">csenner@exelixis.com</font></div><div style="line-height:120%;padding-top:0px;text-align:right;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:right;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;">Susan Hubbard</font></div><div style="line-height:120%;padding-top:0px;text-align:right;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;">EVP, Public Affairs &amp; Investor Relations</font></div><div style="line-height:120%;padding-top:0px;text-align:right;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;">Exelixis, Inc.</font></div><div style="line-height:120%;padding-top:0px;text-align:right;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;">650-837-8194</font></div><div style="line-height:120%;padding-top:0px;text-align:right;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#006ba6;font-style:italic;text-decoration:underline;">shubbard@exelixis.com</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">EXELIXIS </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL </font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">RESULTS </font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">AND PROVIDES CORPORATE UPDATE</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;font-weight:bold;">- Total Revenue of </font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;font-weight:bold;">$240.3</font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;font-weight:bold;">&#32;Million </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-style:italic;font-weight:bold;">for the Fourth Quarter of 2019, </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-style:italic;font-weight:bold;">$967.8</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-style:italic;font-weight:bold;">&#32;Million for the Full Year 2019 -</font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;font-weight:bold;">- GAAP Diluted EPS of </font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;font-weight:bold;">$0.22</font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-style:italic;font-weight:bold;">for the Fourth Quarter of 2019, </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-style:italic;font-weight:bold;">$1.02</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-style:italic;font-weight:bold;">&#32;for the Full Year 2019</font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;font-weight:bold;">&#32;-</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;font-weight:bold;">- Non-GAAP Diluted EPS of </font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;font-weight:bold;">$0.26</font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-style:italic;font-weight:bold;">for the Fourth Quarter of 2019, </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-style:italic;font-weight:bold;">$1.16</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-style:italic;font-weight:bold;">&#32;for the Full Year 2019 </font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;font-weight:bold;">-</font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-style:italic;font-weight:bold;">- Conference Call and Webcast Today at 5:00 PM Eastern Time -</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">ALAMEDA, Calif. - </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">February&#160;25, 2020</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-style:italic;font-weight:bold;">-</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year 2019 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#8220;Exelixis achieved strong financial performance in 2019, with significant growth in total revenue and expansion of the cabozantinib franchise, which for the first time exceeded $1.0 billion in annual global net revenue,&#8221; said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis. &#8220;We concluded the company&#8217;s 25</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;anniversary year with a strong balance sheet and profitable business, which enables Exelixis to continue our ongoing investment to expand the cabozantinib franchise into new indications and build a pipeline of differentiated oncology assets through targeted business development and internal drug discovery activities.&#8221;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">Dr. Morrissey continued: &#8220;Our execution across the commercial, clinical and discovery components of our business in 2019 helped set a strong foundation for Exelixis in 2020, with an impactful lineup of clinical and regulatory milestones expected over the course of the next two years. We ended 2019 with nine ongoing potentially label-enabling trials for cabozantinib, with three additional pivotal trials expected to initiate this year. We&#8217;re anticipating data readouts from six of these ongoing trials in 2020, with the potential for as many as four new approved indications for the cabozantinib franchise by the end of 2021, while rebuilding our oncology pipeline with up to three new investigational new drug filings this year. The entire Exelixis team has worked with focus and determination to advance the business to this point, and we&#8217;re moving decisively to execute on our corporate priorities and bring new medicines forward for the cancer patients that need them.&#8221;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;text-decoration:underline;">Fourth Quarter and Full Year 2019 Financial Results</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-style:italic;">(see Basis of Presentation below for further detail)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Total revenues </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">for the quarter and year ended </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;were </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$240.3 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$967.8 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">, respectively, compared to </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$228.6 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$853.8 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;for the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">2018</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:312px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#160;- more - </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Exelixis Fourth Quarter and Fiscal Year 2019 Financial Results</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Page </font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">2</font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">&#160;of 10</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">February 25, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">Total revenues for the quarter and year ended </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;included net product revenues of </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$194.9 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$760.0 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">, respectively, compared to </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$176.2 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$619.3 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;for the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">2018</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">. The increases in net product revenues reflected the continued growth of CABOMETYX&#174; (cabozantinib) in the U.S. for the treatment of patients with advanced renal cell carcinoma (RCC), as well as the U.S. launch of CABOMETYX for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, following its approval by the U.S. Food and Drug Administration (FDA) in January 2019.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">Total revenues for the quarter and year ended </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;included collaboration revenues of </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$45.4 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$207.8 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">, respectively, compared to </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$52.4 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$234.5 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;for the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">2018</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">. The decreases in collaboration revenues were primarily related to decreases in the recognition of milestone related revenues. These decreases in collaboration revenues were partially offset by higher royalty revenues that were primarily attributed to cabozantinib-related revenues from Exelixis&#8217;&#160;partner Ipsen outside of the U.S.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Research and development expenses</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;for the quarter and year ended </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;were </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$94.4 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$337.0 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">, respectively, compared to </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$57.3 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$182.3 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;for the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">2018</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">. The increases in research and development expenses were primarily related to increases in clinical trial costs, license and other collaboration costs and personnel expenses. The increases in clinical trial costs were primarily due to costs associated with the expanding clinical trial program for cabozantinib, which includes CheckMate 9ER, COSMIC-311, COSMIC-312, COSMIC-313 and COSMIC-021. The increases in license and other collaboration costs were primarily a result of increases in discovery activities with collaboration partners related to in-licensed technology. The increases in personnel expenses were primarily due to increases in headcount to support Exelixis&#8217; expanded discovery and development efforts.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Selling, general and administrative expenses</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;for the quarter and year ended </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;were </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$58.0 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$228.2 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">, respectively, compared to </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$52.4 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$206.4 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;for the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">2018</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">. The increases in selling, general and administrative expenses were primarily related to increases in personnel expenses and stock-based compensation, partially offset by a decrease in corporate giving. The increases in personnel expenses were primarily due to increases in administrative headcount to support Exelixis&#8217; commercial and research and development organizations. The increases in stock-based compensation were primarily due to increases in headcount, as well as the expense recognition for certain of the restricted stock units that were granted in 2018 that either have vested or are expected to vest upon the achievement of specific performance targets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Income tax provision </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">for the quarter and year ended </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;was </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$16.3 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$77.1 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">, respectively, compared to an income tax benefit of </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$243.7 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$238.0 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;for the comparable periods in </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">2018</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">. The provision for income taxes relating to Exelixis&#8217; pre-tax income for the quarter and year ended </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;was more than offset by a valuation allowance against its net operating loss carryforwards and other deferred tax assets. At December 31, 2018, Exelixis released substantially all of the remaining valuation allowance against Exelixis&#8217; deferred tax assets after Exelixis determined that it was more likely than not that these deferred tax assets would be realized.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">GAAP net income </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">for the quarter ended </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;was </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$68.7 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">, or </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$0.23</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;per share, basic and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$0.22</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;per share, diluted, compared to GAAP net income of </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$360.1 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">, or </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$1.20</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;per share, basic and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$1.15</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;per share, diluted, for the comparable period in </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">2018</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">. GAAP net income for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;was </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$321.0 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">, or </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$1.06</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;per share, basic and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$1.02</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;per share, diluted, compared to GAAP net income of </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$690.1 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">, or </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$2.32</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;per share, basic and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$2.21</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;per share, diluted, for the comparable period in </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">2018</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">. The decreases in net income were primarily related to the 2018 release of substantially all of the remaining valuation </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:312px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#160;- more - </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Exelixis Fourth Quarter and Fiscal Year 2019 Financial Results</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Page </font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">3</font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">&#160;of 10</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">February 25, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">allowance against Exelixis&#8217; deferred tax assets, increases in research and development expenses and decreases in milestone revenues; those changes were partially offset by increases in net product revenues.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Non-GAAP net income </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">for the quarter ended </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;was </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$81.0 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">, or </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$0.27</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;per share, basic and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$0.26</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;per share, diluted, compared to non-GAAP net income of </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$128.1 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">, or </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$0.43</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;per share, basic and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$0.41</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;per share, diluted, for the comparable period in </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">2018</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">. Non-GAAP net income</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;was </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$364.9 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">, or </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$1.21</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;per share, basic and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$1.16</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;per share, diluted, compared to non-GAAP net income of </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$485.8 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">, or </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$1.63</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;per share, basic and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$1.55</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;per share, diluted, for the comparable period in </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">2018</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">. Non-GAAP net income excludes the non-cash income tax benefit related to the release of substantially all of the valuation allowance against the company&#8217;s deferred tax assets as of December 31, 2018 described above and stock-based compensation, adjusted for the related income tax effect.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Cash and investments </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">totaled </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$1.4 billion</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;at </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">, compared to </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$0.9 billion</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;at </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;text-decoration:underline;">Non-GAAP Financial Measures</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">To supplement Exelixis&#8217; financial results presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Exelixis presents non-GAAP net income (and the related per share measures), which exclude from GAAP net income (and the related per share measures) the non-cash income tax benefit related to the release of substantially all of the valuation allowance against the company&#8217;s deferred tax assets in 2018 and stock-based compensation expense, adjusted for the related income tax effect for all periods presented. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">Exelixis believes that the presentation of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. In particular, Exelixis believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors&#8217; and analysts&#8217; ability to meaningfully compare Exelixis&#8217; results from period to period, and to identify operating trends in Exelixis&#8217; business. Exelixis has excluded these items because they are non-cash items that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. Exelixis also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Exelixis encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations, to more fully understand Exelixis&#8217; business. Reconciliations between GAAP and non-GAAP results are presented in the tables of this release.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:312px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#160;- more - </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Exelixis Fourth Quarter and Fiscal Year 2019 Financial Results</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Page </font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">4</font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">&#160;of 10</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">February 25, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;text-decoration:underline;">2020 Financial Guidance</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">Exelixis is providing the following financial guidance for fiscal year 2020:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:31%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$850 million - $900 million</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$725 million - $775 million</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cost of goods sold</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4% - 5% of net product revenues</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$460 million - $500 million</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selling, general and administrative expenses</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$230 million - $250 million</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20% - 22%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1.5 billion - $1.6 billion</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Includes $25 million of non-cash stock-based compensation expense.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Includes $30 million of non-cash stock-based compensation expense.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">This cash guidance does not include any potential new business development activity, which remains a key priority for Exelixis as it continues to build toward becoming a multi-product oncology company. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;text-decoration:underline;">Cabozantinib Highlights</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Cabozantinib Full Year 2019 Franchise Net Revenues Exceed $1.0 Billion Globally.</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;Net product revenues generated by the cabozantinib franchise in the U.S. were&#160;</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$194.9 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#160;during the fourth quarter of 2019, an increase of </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">10.6%</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;year-over-year, with net product revenues of </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$181.1 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#160;for CABOMETYX and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">$13.8 million</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;for COMETRIQ&#174; (cabozantinib). Exelixis earned $17.0 million in royalty revenues based upon Ipsen&#8217;s cabozantinib-related revenues in the fourth quarter of 2019</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">. Cabozantinib </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">continues to expand its global footprint, </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">where it is currently approved and commercially available in 52 and 49 countries, respectively. </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">In 2019, global cabozantinib franchise net revenue generated by Exelixis and its partner Ipsen exceeded $1.0 billion for the first time in a calendar year.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Health Canada Approves CABOMETYX for First-Line Treatment of Adults with Advanced RCC.</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#160;In October 2019, Ipsen announced Health Canada&#8217;s approval of CABOMETYX for the first-line treatment of adults with advanced RCC. Under the collaboration agreement with Ipsen, Exelixis received a $3.0 million milestone </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">payment </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">for the Health Canada approval,&#160;which was recognized as revenue in the fourth quarter of 2019. CABOMETYX was originally approved in Canada in September 2018 for the treatment of adults with advanced RCC who have received prior vascular endothelial growth factor targeted therapy.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Health Canada Approves CABOMETYX for the Treatment of Patients with Previously Treated Advanced HCC. </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">In November 2019, Ipsen announced Health Canada&#8217;s approval of CABOMETYX for the treatment of patients with HCC who have been previously treated with sorafenib. Under the collaboration agreement with Ipsen, Exelixis received a $2.0 million milestone payment for the Health Canada approval, which was recognized as revenue in the fourth quarter of 2019.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Announcement of Clinical Collaboration with F. Hoffmann-La Roche Ltd. (Roche) for Three Phase 3 Combination Trials for Patients with Advanced Solid Tumors. </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">In December 2019, Exelixis announced a collaboration agreement with Roche to evaluate cabozantinib in combination with atezolizumab, Roche&#8217;s PD-L1 immune checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. The clinical program, which will be co-funded by the companies, is expected to include three phase 3 pivotal trials in advanced non-small cell lung cancer, metastatic castration-resistant prostate cancer (mCRPC) and RCC.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Further Expansion of Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors. </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">In January 2020, Exelixis announced that based on continued encouraging efficacy and safety data, the company plans to further expand the mCRPC cohort of </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:312px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#160;- more - </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Exelixis Fourth Quarter and Fiscal Year 2019 Financial Results</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Page </font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">5</font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">&#160;of 10</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">February 25, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">COSMIC-021, the phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. The cohort, which was previously expanded from 30 to 80 patients in July 2019, will now include up to 130 patients</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Presentation of Clinical Results from CheckMate 040 Clinical Trial of the Combination of Cabozantinib and Nivolumab with or without Ipilimumab in Advanced HCC. </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">In January 2020, Exelixis announced phase 1/2 clinical trial results from the combination of cabozantinib and nivolumab with or without ipilimumab in advanced HCC. Data from the cabozantinib combination cohort of the CheckMate 040 trial were presented on Friday, January 24</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;at American Society of Clinical Oncology&#8217;s (ASCO) Gastrointestinal Cancers Symposium, which was held in San Francisco, California. These data support Exelixis&#8217; clinical development program of cabozantinib plus immune checkpoint inhibitors in advanced HCC, including the ongoing COSMIC-312 phase 3 pivotal trial of cabozantinib plus atezolizumab versus sorafenib in previously untreated patients.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Readout of Phase 1b COSMIC-021 Trial mCRPC Cohort </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">at ASCO&#8217;s Genitourinary Cancers Symposium</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">. </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">In February 2020, Exelixis announced positive efficacy and safety results from an interim analysis of the mCRPC cohort of COSMIC-021. The data were presented on Thursday, February 13</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;at ASCO</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#8217;s Genitourinary Cancers</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">Symposium, which was held in </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">San Francisco, California. Based on regulatory feedback from the FDA and if supported by the clinical data from the ongoing mCRPC expansion cohorts from COSMIC-021, Exelixis intends to file with the FDA for accelerated approval in an mCRPC indication as early as 2021. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;text-decoration:underline;">Corporate Updates</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Exelixis and Invenra, Inc. (Invenra) Expand Collaboration Focused on the Discovery and Development of Multispecific Antibodies for the Treatment of Cancer. </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">In October 2019, Exelixis expanded its collaboration with Invenra to include the development of novel binders against six additional targets. Under the terms of the expanded collaboration agreement, Exelixis will have the opportunity to use these binders to generate multispecific antibodies based on Invenra&#8217;s B-Body&#8482; technology platform, or with other platforms and formats, at Exelixis&#8217; option.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Exelixis Files Lawsuit to Enforce Its Intellectual Property Rights for CABOMETYX&#160;against Abbreviated New Drug Application (ANDA)&#160;Filer.&#160;</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">In October 2019, Exelixis filed a patent infringement lawsuit against MSN Pharmaceuticals, Inc. (MSN), following receipt of a Paragraph IV certification notice letter from MSN that it had filed an ANDA with the FDA requesting approval to market a generic version of CABOMETYX tablets, following expiration of the CABOMETYX composition of matter patent, U.S. Patent No. 7,579,473, which expires on August 14, 2026. Exelixis is seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of U.S. Patent No. 8,877,776 on October 8, 2030 and equitable relief enjoining MSN from infringing this patent.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Exelixis&#8217; Collaborator Daiichi Sankyo </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Company, Limited (Daiichi Sankyo) </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Announces Positive Results from Phase 3 Pivotal Trial of Esaxerenone in Patients with Diabetic Nephropathy. </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">In November 2019, Exelixis announced that its partner Daiichi Sankyo reported positive results from a phase 3 pivotal trial of esaxerenone in patients with diabetic nephropathy. Esaxerenone is a novel mineralocorticoid receptor blocker identified during the prior research collaboration between Exelixis and Daiichi Sankyo and subsequently developed and commercialized by Daiichi Sankyo. Esaxerenone has been approved as a treatment for patients with hypertension in Japan, where it is marketed as MINNEBRO&#174; tablets. Daiichi Sankyo is solely responsible for esaxerenone&#8217;s development and commercialization, with Exelixis remaining eligible for substantial commercialization milestones, as well as low double-digit royalties on sales, as it advances.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Announcement of Positive Results from IMspire150.</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;In December 2019, Exelixis announced positive results from IMspire150, the phase 3 trial of atezolizumab, cobimetinib and vemurafenib in people with previously </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:312px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#160;- more - </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Exelixis Fourth Quarter and Fiscal Year 2019 Financial Results</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Page </font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">6</font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">&#160;of 10</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">February 25, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">untreated BRAF V600 mutation-positive advanced melanoma. Genentech, Inc. (a member of the Roche Group), Exelixis&#8217; collaborator and the sponsor of the IMspire150 trial, informed Exelixis that the study met its primary endpoint of progression-free survival. Results will be presented at an upcoming medical meeting and discussed with health authorities around the world, including the FDA and the European Medicines Agency. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21. </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">In January 2020, Exelixis announced its key priorities and anticipated milestones for 2020-21, including generating top-line data from as many as six ongoing trials with label-enabling potential, initiating at least three new pivotal trials, and progressing its mid-stage and early pipeline, with up to three new investigational new drug filings in 2020. The company intends to make appropriate investments to maximize the clinical development opportunities for CABOMETYX, which Exelixis believes could lead to as many as four additional approved indications by year-end 2021, while concurrently working to advance a pipeline of potential new Exelixis medicines through internal drug discovery and business development.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;text-decoration:underline;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">Exelixis has adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December 31</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">. For convenience, references in this press release as of and for the fiscal periods ended January 3, 2020 and December 28, 2018 are indicated as being as of and for the periods ended December 31, 2019 and December 31, 2018, respectively. The periods ended December 31, 2019 were a 14-week fiscal quarter and a 53-week fiscal year, as compared to a 13-week fiscal quarter and a 52-week fiscal year for the comparable the periods in 2018.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;text-decoration:underline;">Conference Call and Webcast</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">Exelixis management will discuss the company&#8217;s financial results for the fourth quarter and full year 2019 and provide a general business update during a conference call beginning at 5:00 p.m. ET / 2:00 p.m. PT today, Tuesday, February 25, 2020.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">To access the webcast link, log onto </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#006ebf;text-decoration:underline;">www.exelixis.com</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;and proceed to the News &amp; Events / Event Calendar page under the Investors &amp; Media heading. Please connect to the company&#8217;s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please cal</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">l </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#006ebf;text-decoration:underline;">855-793-2457</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;(domestic) or </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#006ebf;text-decoration:underline;">631-485-4921</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;(inte</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">rnational) and provide the conference call passcode 9168158</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">to join by phone.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">A telephone replay will be available until 8:00 p.m. ET on </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">February 27, 2020</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">. Access numbers for the telephone re</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">play are: </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#006ebf;text-decoration:underline;">855-859-2056</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;(domestic) and </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#006ebf;text-decoration:underline;">404-537-3406</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;(inte</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">rnational); the passcode is 9168158. A webcast replay will also be archived on </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#006ebf;text-decoration:underline;">www.exelixis.com</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;for one year.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;text-decoration:underline;">About Exelixis</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">Founded in 1994,&#160;Exelixis, Inc.&#160;(Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four approved products, CABOMETYX&#174; </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">(cabozantinib), COMETRIQ</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#174;</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#160;(cabozantinib), COTELLIC</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#174; </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">(cobimetinib) and MINNEBRO</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#174;</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;(esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:312px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#160;- more - </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Exelixis Fourth Quarter and Fiscal Year 2019 Financial Results</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Page </font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">7</font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">&#160;of 10</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">February 25, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">existing therapeutic assets with targeted business development activities and internal drug discovery - all to deliver the next generation of&#160;Exelixis&#160;medicines and help patients recover stronger and live longer.&#160;Exelixis&#160;is a member of Standard &amp; Poor&#8217;s (S&amp;P) MidCap 400 index, which measures the performance of profitable mid-sized companies. For more information about&#160;Exelixis, please visit&#160;</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#006ebf;text-decoration:underline;">www.exelixis.com</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">, follow </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#006ebf;">@ExelixisInc</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;on Twitter or like </font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#006ebf;">Exelixis, Inc.</font><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#32;on Facebook.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-weight:bold;text-decoration:underline;">Forward-Looking Statements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">This press release contains forward-looking statements, including, without limitation, statements related to: Exelixis&#8217; expectation to achieve an impactful lineup of clinical and regulatory milestones over the next two years, including data readouts from six of its nine ongoing potentially label-enabling trials for cabozantinib in 2020, with the potential for as many as four new approved indications for the cabozantinib franchise by the end of 2021, the initiation of three additional pivotal trials in non-small cell lung cancer, mCRPC and RCC in 2020 and a rebuilding of Exelixis&#8217; oncology pipeline with up to three new investigational new drug filings in 2020; Exelixis&#8217; updated 2020 financial guidance; Exelixis&#8217; plans to further expand the mCRPC cohort of COSMIC-021 to include up to 130 patients; Exelixis&#8217; intention to file with the&#160;FDA&#160;for accelerated approval of the combination of cabozantinib and atezolizumab in a mCRPC indication as early as 2021, if supported by the clinical data; Exelixis&#8217; obligations under its collaboration agreement with Invenra; Exelixis&#8217; eligibility for substantial commercialization milestones, as well as low double-digit royalties on sales of MINNEBRO; Genentech&#8217;s plans to present the IMspire150 data at an upcoming medical meeting and discuss the data with health authorities around the world; and Exelixis&#8217; plans to reinvest in its business to maximize the potential of the company&#8217;s pipeline, including through targeted business development activities and internal drug discovery. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis&#8217; current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the degree of market acceptance of CABOMETYX, COMETRIQ, COTELLIC and MINNEBRO in the territories where they are approved, and Exelixis&#8217; ability to obtain or maintain coverage and reimbursement for these products; the effectiveness of CABOMETYX, COMETRIQ, COTELLIC and MINNEBRO in comparison to competing products; the level of costs associated with Exelixis&#8217; commercialization, research and development, in-licensing or acquisition of product candidates, and other activities; the availability of data at the referenced times; the potential failure of cabozantinib and other&#160;Exelixis&#160;product candidates, both alone and in combination with other therapies, to demonstrate safety and/or efficacy in clinical testing; uncertainties inherent in the drug discovery and product development process, including evolving regulatory requirements, slower than anticipated patient enrollment, inability to identify a sufficient number of clinical trial sites or limited availability of third-party scientific advisors and contractors; Exelixis&#8217; dependence on its relationships with its collaboration partners, including their pursuit of regulatory approvals for partnered compounds in new indications, their adherence to their obligations under relevant collaboration agreements and the level of their investment in the resources necessary to complete clinical trials or successfully commercialize partnered compounds in the territories where they are approved; the regulatory review and approval processes, including the risk that regulatory authorities may not approve Exelixis&#8217; products as treatments for the indications in which approval has been sought; Exelixis&#8217; continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib, cobimetinib or esaxerenone; Exelixis&#8217; dependence on third-party vendors for the manufacture and supply of its products; Exelixis&#8217; ability to protect its intellectual property rights; market competition, including the potential for competitors to obtain approval for generic versions of Exelixis&#8217; marketed products; changes in economic and business conditions; and other factors discussed under the caption &#8220;Risk Factors&#8221; in Exelixis&#8217; Quarterly Report on Form 10-Q filed with the&#160;Securities and Exchange Commission&#160;(SEC) on&#160;October 30, 2019, and in Exelixis&#8217; future filings with the&#160;SEC, including, without limitation, Exelixis&#8217; Annual Report on Form 10-K expected to be </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:312px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#160;- more - </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Exelixis Fourth Quarter and Fiscal Year 2019 Financial Results</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Page </font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">8</font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">&#160;of 10</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">February 25, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">filed with the&#160;SEC&#160;on&#160;February 25, 2020. All forward-looking statements in this press release are based on information available to&#160;Exelixis&#160;as of the date of this press release, and&#160;Exelixis&#160;undertakes no obligation to update or revise any forward-looking statements contained herein.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:174%;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-style:italic;">Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks.</font></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;font-style:italic;">MINNEBRO is a registered Japanese trademark.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">-see attached financial tables-</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:312px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#160;- more - </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div><a name="s0E62C810581659698E1A0A0980387246"></a></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Exelixis Fourth Quarter and Fiscal Year 2019 Financial Results</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Page </font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">9</font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">&#160;of 10</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">February 25, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">(in thousands, except per share amounts)</font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">(unaudited)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Net product revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">194,926</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">176,225</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">759,950</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">619,279</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Collaboration revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">45,384</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">52,377</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">207,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">234,547</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">240,310</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">228,602</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">967,775</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">853,826</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">10,520</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">7,352</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">33,097</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">26,348</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">94,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">57,271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">336,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">182,257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">58,026</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">52,377</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">228,244</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">206,366</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">162,994</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">117,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">598,305</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">414,971</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Income from operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">77,316</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">111,602</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">369,470</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">438,855</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Other income (expense), net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">7,706</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">4,741</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">27,959</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">12,840</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">680</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">397</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Total other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">7,698</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">4,770</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">28,639</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">13,237</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Income before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">85,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">116,372</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">398,109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">452,092</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Income tax provision (benefit)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">16,271</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">(243,717</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">77,097</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">(237,978</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Net income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">68,743</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">360,089</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">321,012</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">690,070</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Net income per share, basic </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">0.23</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">1.20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">1.06</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">2.32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Net income per share, diluted </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">0.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">1.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">1.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">2.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Shares used in computing net income per share, basic </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">304,338</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">299,409</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">302,584</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">297,892</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Shares used in computing net income per share, diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">315,030</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">312,443</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">315,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">312,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:312px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#160;- more - </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Exelixis Fourth Quarter and Fiscal Year 2019 Financial Results</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Page </font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">10</font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">&#160;of 10</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">February 25, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEET DATA</font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">(in thousands)</font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">(unaudited)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;text-indent:2px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Cash and investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">1,388,628</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">851,621</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Working capital</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">868,444</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">791,544</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Total assets</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">1,885,670</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">1,422,286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Total stockholders&#8217; equity</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">1,685,970</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">1,287,453</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s86F3F436C3AD5983AC2AC327FB83C0F2"></a></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">RECONCILIATION OF GAAP NET INCOME TO NON-GAAP NET INCOME </font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">(in thousands, except per share amounts)</font></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">(unaudited)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">GAAP net income</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">68,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">360,089</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">321,012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">690,070</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adjustments:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation - research and development expenses </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,629</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19,374</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation - selling, general and administrative expenses </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,226</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,283</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37,228</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,511</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax effect of the above adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(12,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(787</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax benefit resulting from the release of the valuation allowance </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(244,111</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(244,111</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Non-GAAP net income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">81,031</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">128,054</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">364,899</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">485,798</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">GAAP net income per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.23</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.20</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.06</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.32</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">GAAP net income per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Non-GAAP net income per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.43</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.63</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Non-GAAP net income per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Shares used in computing net income per share, basic </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">304,338</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">299,409</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">302,584</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">297,892</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Shares used in computing net income per share, diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">315,030</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,443</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">315,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:48px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#000000;"></font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Non-cash stock-based compensation expense used for GAAP reporting in accordance with Accounting Standards Codification Topic 718, </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:italic;">Compensation&#8212;Stock Compensation</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Represents the non-cash income tax benefit related to the release of substantially all of the valuation allowance against the company&#8217;s deferred tax assets on December 31, 2018.</font></div></td></tr></table><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>exel-20200225.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelicis.com/20200225" xmlns:exel="http://www.exelicis.com/20200225" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20200225_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20200225_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20200225_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20200225_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CoverPage" roleURI="http://www.exelicis.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>exel-20200225_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelicis.com/role/CoverPage" xlink:href="exel-20200225.xsd#CoverPage" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.exelicis.com/role/CoverPage" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>exel-20200225_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelicis.com/role/CoverPage" xlink:href="exel-20200225.xsd#CoverPage" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.exelicis.com/role/CoverPage" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>exel-20200225_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6_label_en-US" xlink:label="lab_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="lab_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_2D2D958F1ADA640B232A5F3652381C88_terseLabel_en-US" xlink:label="lab_dei_DocumentType_2D2D958F1ADA640B232A5F3652381C88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_2D2D958F1ADA640B232A5F3652381C88_label_en-US" xlink:label="lab_dei_DocumentType_2D2D958F1ADA640B232A5F3652381C88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_2D2D958F1ADA640B232A5F3652381C88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_2D2D958F1ADA640B232A5F3652381C88" xlink:to="lab_dei_DocumentType_2D2D958F1ADA640B232A5F3652381C88" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_1EE7125E717EF79BC2755F365239E6B5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_1EE7125E717EF79BC2755F365239E6B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_1EE7125E717EF79BC2755F365239E6B5_label_en-US" xlink:label="lab_dei_AmendmentFlag_1EE7125E717EF79BC2755F365239E6B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1EE7125E717EF79BC2755F365239E6B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_1EE7125E717EF79BC2755F365239E6B5" xlink:to="lab_dei_AmendmentFlag_1EE7125E717EF79BC2755F365239E6B5" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_E6CAA0EFFFFFEE023C8F5F36523A2F76_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_E6CAA0EFFFFFEE023C8F5F36523A2F76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_E6CAA0EFFFFFEE023C8F5F36523A2F76_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_E6CAA0EFFFFFEE023C8F5F36523A2F76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_E6CAA0EFFFFFEE023C8F5F36523A2F76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_E6CAA0EFFFFFEE023C8F5F36523A2F76" xlink:to="lab_dei_DocumentPeriodEndDate_E6CAA0EFFFFFEE023C8F5F36523A2F76" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_1ABB65946C6D8A7A07B15F36523AB2F2_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_1ABB65946C6D8A7A07B15F36523AB2F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_1ABB65946C6D8A7A07B15F36523AB2F2_label_en-US" xlink:label="lab_dei_EntityRegistrantName_1ABB65946C6D8A7A07B15F36523AB2F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1ABB65946C6D8A7A07B15F36523AB2F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_1ABB65946C6D8A7A07B15F36523AB2F2" xlink:to="lab_dei_EntityRegistrantName_1ABB65946C6D8A7A07B15F36523AB2F2" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_B9CC0F895D9A7CE03CD75F36523A010B_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_B9CC0F895D9A7CE03CD75F36523A010B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_B9CC0F895D9A7CE03CD75F36523A010B_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_B9CC0F895D9A7CE03CD75F36523A010B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_B9CC0F895D9A7CE03CD75F36523A010B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_B9CC0F895D9A7CE03CD75F36523A010B" xlink:to="lab_dei_EntityCentralIndexKey_B9CC0F895D9A7CE03CD75F36523A010B" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_B9E256A89468466D2BC75F36523B9399_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_B9E256A89468466D2BC75F36523B9399" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_B9E256A89468466D2BC75F36523B9399_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_B9E256A89468466D2BC75F36523B9399" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_B9E256A89468466D2BC75F36523B9399" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_B9E256A89468466D2BC75F36523B9399" xlink:to="lab_dei_EntityEmergingGrowthCompany_B9E256A89468466D2BC75F36523B9399" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_F1EA66F0653AFA7811CF5F36523BD5D4_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_F1EA66F0653AFA7811CF5F36523BD5D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_F1EA66F0653AFA7811CF5F36523BD5D4_label_en-US" xlink:label="lab_dei_Security12bTitle_F1EA66F0653AFA7811CF5F36523BD5D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_F1EA66F0653AFA7811CF5F36523BD5D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_F1EA66F0653AFA7811CF5F36523BD5D4" xlink:to="lab_dei_Security12bTitle_F1EA66F0653AFA7811CF5F36523BD5D4" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_C1290D51C00668CFA8AA5F36523BFD8B_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_C1290D51C00668CFA8AA5F36523BFD8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_C1290D51C00668CFA8AA5F36523BFD8B_label_en-US" xlink:label="lab_dei_TradingSymbol_C1290D51C00668CFA8AA5F36523BFD8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_C1290D51C00668CFA8AA5F36523BFD8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_C1290D51C00668CFA8AA5F36523BFD8B" xlink:to="lab_dei_TradingSymbol_C1290D51C00668CFA8AA5F36523BFD8B" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_0CA2D90CEEB94C73B0465F36523B84EE_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_0CA2D90CEEB94C73B0465F36523B84EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_0CA2D90CEEB94C73B0465F36523B84EE_label_en-US" xlink:label="lab_dei_SecurityExchangeName_0CA2D90CEEB94C73B0465F36523B84EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_0CA2D90CEEB94C73B0465F36523B84EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_0CA2D90CEEB94C73B0465F36523B84EE" xlink:to="lab_dei_SecurityExchangeName_0CA2D90CEEB94C73B0465F36523B84EE" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_40F356ADA5BE282FD6C95F36523B35AE_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_40F356ADA5BE282FD6C95F36523B35AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_40F356ADA5BE282FD6C95F36523B35AE_label_en-US" xlink:label="lab_dei_EntityFileNumber_40F356ADA5BE282FD6C95F36523B35AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_40F356ADA5BE282FD6C95F36523B35AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_40F356ADA5BE282FD6C95F36523B35AE" xlink:to="lab_dei_EntityFileNumber_40F356ADA5BE282FD6C95F36523B35AE" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_3A4F219FBF4F1809BD485F36523B9118_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_3A4F219FBF4F1809BD485F36523B9118" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_3A4F219FBF4F1809BD485F36523B9118_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_3A4F219FBF4F1809BD485F36523B9118" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3A4F219FBF4F1809BD485F36523B9118" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_3A4F219FBF4F1809BD485F36523B9118" xlink:to="lab_dei_EntityIncorporationStateCountryCode_3A4F219FBF4F1809BD485F36523B9118" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3902FE9DE576656D66B35F36523C6015_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_3902FE9DE576656D66B35F36523C6015" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3902FE9DE576656D66B35F36523C6015_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_3902FE9DE576656D66B35F36523C6015" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_3902FE9DE576656D66B35F36523C6015" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_3902FE9DE576656D66B35F36523C6015" xlink:to="lab_dei_EntityTaxIdentificationNumber_3902FE9DE576656D66B35F36523C6015" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_81AF2D58C515B01EE3CA5F36523C4EED_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_81AF2D58C515B01EE3CA5F36523C4EED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_81AF2D58C515B01EE3CA5F36523C4EED_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_81AF2D58C515B01EE3CA5F36523C4EED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_81AF2D58C515B01EE3CA5F36523C4EED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_81AF2D58C515B01EE3CA5F36523C4EED" xlink:to="lab_dei_EntityAddressAddressLine1_81AF2D58C515B01EE3CA5F36523C4EED" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_FE7C3A4ED9D5848925965F36523CC63F_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_FE7C3A4ED9D5848925965F36523CC63F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_FE7C3A4ED9D5848925965F36523CC63F_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_FE7C3A4ED9D5848925965F36523CC63F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_FE7C3A4ED9D5848925965F36523CC63F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_FE7C3A4ED9D5848925965F36523CC63F" xlink:to="lab_dei_EntityAddressCityOrTown_FE7C3A4ED9D5848925965F36523CC63F" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_856AF143A6B2180989F95F36523C5869_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_856AF143A6B2180989F95F36523C5869" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_856AF143A6B2180989F95F36523C5869_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_856AF143A6B2180989F95F36523C5869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_856AF143A6B2180989F95F36523C5869" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_856AF143A6B2180989F95F36523C5869" xlink:to="lab_dei_EntityAddressStateOrProvince_856AF143A6B2180989F95F36523C5869" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_FB19508D788CBDB2DE525F36523C96BA_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_FB19508D788CBDB2DE525F36523C96BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_FB19508D788CBDB2DE525F36523C96BA_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_FB19508D788CBDB2DE525F36523C96BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_FB19508D788CBDB2DE525F36523C96BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_FB19508D788CBDB2DE525F36523C96BA" xlink:to="lab_dei_EntityAddressPostalZipCode_FB19508D788CBDB2DE525F36523C96BA" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_863E973E41CEF855EF3F5F36523D6F44_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_863E973E41CEF855EF3F5F36523D6F44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_863E973E41CEF855EF3F5F36523D6F44_label_en-US" xlink:label="lab_dei_CityAreaCode_863E973E41CEF855EF3F5F36523D6F44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_863E973E41CEF855EF3F5F36523D6F44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_863E973E41CEF855EF3F5F36523D6F44" xlink:to="lab_dei_CityAreaCode_863E973E41CEF855EF3F5F36523D6F44" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_8DCA8480AA740E39478F5F36523DD599_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_8DCA8480AA740E39478F5F36523DD599" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_8DCA8480AA740E39478F5F36523DD599_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_8DCA8480AA740E39478F5F36523DD599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_8DCA8480AA740E39478F5F36523DD599" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_8DCA8480AA740E39478F5F36523DD599" xlink:to="lab_dei_LocalPhoneNumber_8DCA8480AA740E39478F5F36523DD599" xlink:type="arc" />
    <link:label id="lab_dei_WrittenCommunications_6CE2B0D3035C0D2E17135F36523D5C39_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications_6CE2B0D3035C0D2E17135F36523D5C39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_6CE2B0D3035C0D2E17135F36523D5C39_label_en-US" xlink:label="lab_dei_WrittenCommunications_6CE2B0D3035C0D2E17135F36523D5C39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_6CE2B0D3035C0D2E17135F36523D5C39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications_6CE2B0D3035C0D2E17135F36523D5C39" xlink:to="lab_dei_WrittenCommunications_6CE2B0D3035C0D2E17135F36523D5C39" xlink:type="arc" />
    <link:label id="lab_dei_SolicitingMaterial_8C80C7DAD16FBC0EF7CE5F36523D2446_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial_8C80C7DAD16FBC0EF7CE5F36523D2446" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_8C80C7DAD16FBC0EF7CE5F36523D2446_label_en-US" xlink:label="lab_dei_SolicitingMaterial_8C80C7DAD16FBC0EF7CE5F36523D2446" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_8C80C7DAD16FBC0EF7CE5F36523D2446" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial_8C80C7DAD16FBC0EF7CE5F36523D2446" xlink:to="lab_dei_SolicitingMaterial_8C80C7DAD16FBC0EF7CE5F36523D2446" xlink:type="arc" />
    <link:label id="lab_dei_PreCommencementTenderOffer_054AAE8B941EB0EBD1515F36523D9D14_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer_054AAE8B941EB0EBD1515F36523D9D14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_054AAE8B941EB0EBD1515F36523D9D14_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer_054AAE8B941EB0EBD1515F36523D9D14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_054AAE8B941EB0EBD1515F36523D9D14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer_054AAE8B941EB0EBD1515F36523D9D14" xlink:to="lab_dei_PreCommencementTenderOffer_054AAE8B941EB0EBD1515F36523D9D14" xlink:type="arc" />
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_CF9E55FB799B9199707C5F36523D2C1E_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer_CF9E55FB799B9199707C5F36523D2C1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_CF9E55FB799B9199707C5F36523D2C1E_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer_CF9E55FB799B9199707C5F36523D2C1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_CF9E55FB799B9199707C5F36523D2C1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer_CF9E55FB799B9199707C5F36523D2C1E" xlink:to="lab_dei_PreCommencementIssuerTenderOffer_CF9E55FB799B9199707C5F36523D2C1E" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>exel-20200225_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelicis.com/role/CoverPage" xlink:href="exel-20200225.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.exelicis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_2D2D958F1ADA640B232A5F3652381C88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_DocumentType_2D2D958F1ADA640B232A5F3652381C88" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1EE7125E717EF79BC2755F365239E6B5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_AmendmentFlag_1EE7125E717EF79BC2755F365239E6B5" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_E6CAA0EFFFFFEE023C8F5F36523A2F76" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_DocumentPeriodEndDate_E6CAA0EFFFFFEE023C8F5F36523A2F76" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1ABB65946C6D8A7A07B15F36523AB2F2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_EntityRegistrantName_1ABB65946C6D8A7A07B15F36523AB2F2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_B9CC0F895D9A7CE03CD75F36523A010B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_EntityCentralIndexKey_B9CC0F895D9A7CE03CD75F36523A010B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_B9E256A89468466D2BC75F36523B9399" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_EntityEmergingGrowthCompany_B9E256A89468466D2BC75F36523B9399" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_F1EA66F0653AFA7811CF5F36523BD5D4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_Security12bTitle_F1EA66F0653AFA7811CF5F36523BD5D4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_C1290D51C00668CFA8AA5F36523BFD8B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_TradingSymbol_C1290D51C00668CFA8AA5F36523BFD8B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_0CA2D90CEEB94C73B0465F36523B84EE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_SecurityExchangeName_0CA2D90CEEB94C73B0465F36523B84EE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_40F356ADA5BE282FD6C95F36523B35AE" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_EntityFileNumber_40F356ADA5BE282FD6C95F36523B35AE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3A4F219FBF4F1809BD485F36523B9118" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3A4F219FBF4F1809BD485F36523B9118" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_3902FE9DE576656D66B35F36523C6015" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_EntityTaxIdentificationNumber_3902FE9DE576656D66B35F36523C6015" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_81AF2D58C515B01EE3CA5F36523C4EED" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_EntityAddressAddressLine1_81AF2D58C515B01EE3CA5F36523C4EED" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_FE7C3A4ED9D5848925965F36523CC63F" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_EntityAddressCityOrTown_FE7C3A4ED9D5848925965F36523CC63F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_856AF143A6B2180989F95F36523C5869" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_EntityAddressStateOrProvince_856AF143A6B2180989F95F36523C5869" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_FB19508D788CBDB2DE525F36523C96BA" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_EntityAddressPostalZipCode_FB19508D788CBDB2DE525F36523C96BA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_863E973E41CEF855EF3F5F36523D6F44" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_CityAreaCode_863E973E41CEF855EF3F5F36523D6F44" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_8DCA8480AA740E39478F5F36523DD599" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_LocalPhoneNumber_8DCA8480AA740E39478F5F36523DD599" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_6CE2B0D3035C0D2E17135F36523D5C39" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_WrittenCommunications_6CE2B0D3035C0D2E17135F36523D5C39" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_8C80C7DAD16FBC0EF7CE5F36523D2446" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_SolicitingMaterial_8C80C7DAD16FBC0EF7CE5F36523D2446" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_054AAE8B941EB0EBD1515F36523D9D14" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_PreCommencementTenderOffer_054AAE8B941EB0EBD1515F36523D9D14" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_CF9E55FB799B9199707C5F36523D2C1E" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_A3785A1FECB943CA7A3C5F36523339F6" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_CF9E55FB799B9199707C5F36523D2C1E" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>exellogo18q3a10.jpg
<TEXT>
begin 644 exellogo18q3a10.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M                ]M8  0    #3+4A0("
M                                     !%C<')T   !4    #-D97-C
M   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G
M6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q
M (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $
M#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A
M8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M             !)S4D="($E%0S8Q.38V+3(N,0
M                                            6%E:(        /-1
M  $    !%LQ865H@                     %A96B        !OH@  ./4
M  .06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E
M<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:
M                          !D97-C         "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                            9&5S8P         L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                             '9I97<      !.D_@ 47RX $,\4  /M
MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                         H\    "<VEG(     !#4E0@8W5R=@
M  0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C
M &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -
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MUTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\
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MNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$
M P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0
M 0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E
M\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'
MR,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*.(L5GN:5LUQC]^K)NW1+:,5Y15DO)!1117K'@A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY2I[]%'7\:^/:*_%,P\3N(\7*[Q#@NT$HI?-+F^]L_I;*/!'@W 045@U4?\
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M5D?Y@YACZ^-Q-3&8J7-4J2<I-]6W=O[PHHHKH.,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKE?C?X\_X57\&O%?B4;=V@Z1=7Z
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MTL DV[EMX_O22L/[J(&8^RFOW/\ A9\-=*^#GPYT;POHL/V?2]#M4M8%/WF
MZLQ[LS$L3W+$U\>?\$9?V5/^$)\ 7?Q,U>WVZIXF1K725=>8+)6&Z3D<&5UX
M_P!B-2.'-?<E?U1X1<*_V=EO]HUU^]KV:\H?97_;WQ/RY>Q_"?TA.._[7SG^
MQ\+*]#"MIVVE4VD_^W?A79\W1A1117Z\?SV%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0H YK^AO ?FOC>W[O[_?/Y%^E5R6RQ?:_??=^Z+%%%%?T,?R"%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_16OB9_X5-]_P#':/\ AM;XR?\ 16OB9_X5-]_\=KS+YO:CYO:BR"[/3?\
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M5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_T5KXF?\
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MXI?$:\L[SQ%I\$\$_B2\DBGC:YC5D93(0RD$@@C!!K]YJ_G4_9>_Y.5^'?\
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M5E9205((()!K]UJ_GG_8I_Y/(^$O_8Y:/_Z70U_0Q6-3<TAL%%%%9EA1110
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M66\G^2Z)+HE9):)!1117<>6%%%% !1110 5^<?\ P5H_;Y_MBYO/A3X-OO\
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M5.S/V:HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV_:@^("^-?%5GN\ ^&;@8AE7Y=:NUPPAP>#$G!D['(3G+$?LJB+$BJJA548
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MKF/F]JZ?X*_\EC\)?]AFS_\ 1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@
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MYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OVC_X(E_
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MF]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]JU? W@;6/B9XOT
M[P_X?TZZU;6=6F6WM+2W3=),Y[#VZDDX  ). ":0'UG_ ,$0O@'-\4_VPHO$
MTT!?2? -H]_(Y'R&YE5H8$_WN9)!_P!<?P/[.UX;_P $^?V.K3]BW]GNQ\.L
MT-UXAU!OM^N7<?W9KIE V(3SY<:@(O3."V 6(KW*N>4KLVBK(****DH****
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M1110 4444 %4M?U^Q\*:'>:GJ5U;V.GV$+3W%S.X2."-1EF8G@  5=K\O_\
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M-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4
M'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U
M'S>U'S>U !\WM4NG:C<:3J$-W:3S6MU:R+-#-"Y22)U.596'(8$ @CD$9J+Y
MO:K.AZ)>>)M:M-.T^UFO+^_F2WM[>%"\D\CD*J*!R220 /4T ?K1_P $D/\
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M"OA'2X=)T?3Q\L:?,\SG[TDCGEY&QRQY.!V  ZRBBLS0**** "BBB@ HHHH
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MQ#:V=G$T\\\SA(X8U!+,S'@* "23P *_$/\ X*@_M]W7[9OQ:-CH\\T/P_\
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M[DRV/RZ^;VH^;VH^;VH^;VKI,0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:OT"_X(5?L_>!_CJ?BE_PF7A70O$W]E_V3]C_ +1M$N/LWF?;
M=^S<#C=L3..NT>E*3LKC2N?G[\WM1\WM7] O_#O[X(_]$K\"_P#@HB_PH_X=
M_?!'_HE?@7_P41?X5G[5%^S9_/U\WM1\WM7] O\ P[^^"/\ T2OP+_X*(O\
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M_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444 %%%% !1110
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M1YG5A[P&OR>^;VK:G'2YE-ZV#YO:CYO:CYO:CYO:M2 ^;VH^;VH^;VH^;VH
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M* "BBB@#^?G_ (*!_P#)[GQ5_P"QFOO_ $:U>0?-[5Z__P % _\ D]SXJ_\
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MH#GCY4\Z3\I)I!_P&OE+YO:NW_:;\7GX@?M'>/M<,GF#5O$5_=J<Y&U[B1E
MZ\ $ >PKB/F]JZH[&#W#YO:CYO:CYO:CYO:F(/F]J/F]J/F]J/F]J #YO:CY
MO:CYO:CYO:@#[)_X(Y?L.V?[3WQANO%7B:U6Z\'^"7CD-M(,QZE>M\T43#^*
M- "[CO\ (I!5FK]G%4(N!P!T'I7S7_P2/^%T/PO_ &#/!02-4NO$,<NMW;C_
M ):O/(2A/TA6%?\ @-?2E<TI79M%604445)04444 %%%% !1110 4444 >7_
M +1_[&_PY_:NT7[+XU\-V>H7,:;+?48AY-_:?[DR_-@'G:<H3U4U^<?[2_\
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ML%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\G_ &S/V2M!_;*^"5]X3UC;;W8_TC2M1";I--N@#MD'
MJIY5E_B5CT."/6** /YO_C!\(]>^!'Q*U?PGXFLFT_6M%G,%Q$>5/=70_P 2
M,I#*W0J0>]<U\WM7[3_\%8?^">Z?M:?#3_A)_#-JO_"PO"\#&W5!SK%L,LUJ
M?]L'+1G^\2O ?*_BU<6\EI<20S1O#-$Q1T<;61AP01V(KIC*Z,91L-^;VH^;
MVH^;VH^;VJB0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OU9_X(P_\
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MK_R6/PE_V&;/_P!'I7,?-[5T_P %?^2Q^$O^PS9_^CTI ?T?4445RG0%%%%
M!1110 4444 ?S.W5S)>W4DTK&269B[L>K,3DDTSYO:G7%O):7$D4BM')&Q1U
M88*D<$&F_-[5UG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-
M[4?-[4 ?O[_P3LU^U\2_L-?"VXLS&88_#UM:MY9./,A7R9.YYWQMGWSTZ#VB
MOR]_X(=?MSZ;X6@F^#OBB]CLUO+IKOPU<SOMC:60CS+/)X4LWSH/XF:09W%
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ML%%%%24%%%% !1110 4444 %%%% !1110 5^;_\ P<0_\B9\+?\ K\U'_P!
MMZ_2"OS?_P"#B'_D3/A;_P!?FH_^@6]5'<F6Q^77S>U'S>U'S>U'S>U=)B'S
M>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^F?_!NGT^,7_<%_]R%?F9\W
MM7Z9_P#!NGT^,7_<%_\ <A45/A*CN?IE1117.;!1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX9_\#9_\*/\ B(7\9?\ 1._#/_@;/_A1R,.9'ZM45^4O_$0OXR_Z)WX9_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\
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M_K,_@,**** "BBB@ HHHH **** "BBB@ HHHH *^9?\ @L5_RCC^(W_<-_\
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M?L1?#W0[J-H;Y]-_M&Y1AATDNI'N2K?[2B4+[;<5E4V+I[GN-%%%8FH4444
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M]M3P=^VG\/?[9\,W#6^H6>U-4TBX8?:M-D.<!AT9&P=LB\, >C!E'K]?SD?
MOXZ>)OV<?B9IWBSPGJ,FFZQIK<'[T=Q&?O12KT>-@,%3[$8(!'[G_L.?MH^'
M_P!M?X/PZ_I?EV6M6.V#6M*+[I-/G(SQW:-\$H_<9!PRL!C.%C:,KGM%%%%9
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?S\_\% _^3W/BK_V,U]_Z-:O(/F]
MJ]?_ ."@?_)[GQ5_[&:^_P#1K5Y!\WM75'8YP^;VH^;VH^;VH^;VI@'S>U'S
M>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S
M>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1
M\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U>R_L?_ +"WCS]L[Q>E
MGX;L&M=%@D"ZAKEVC+96*\9&[_EI)@\1KR<@G:N6"O8#H_\ @F9^QS<_M??M
M(:?:W5JTGA'P[)'J.O2L/W;Q*V4M\_WIF7;CKM#L/NU^[JJ$7 X Z#TKS?\
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M% !1110 5^;_ /P<0_\ (F?"W_K\U'_T"WK](*_-_P#X.(?^1,^%O_7YJ/\
MZ!;U4=R9;'Y=?-[4?-[4?-[4?-[5TF(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U
M'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\W
MM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\W
MM1\WM0 ?-[4?-[4?-[4?-[4 'S>U7?#'AG4/&GB.QTC2;.?4-3U*=+:UMH5W
M23RN0JJH]22*L^!? 6M?$[Q59Z'X=TN^UK5]0<1V]I9PF660^P'8=23P!R<
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MVH^;VH^;VH /F]JZ?X*_\EC\)?\ 89L__1Z5S'S>U=/\%?\ DL?A+_L,V?\
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M_NRC_B'3_P"JQ?\ EJ?_ '97Z944<\@Y4?F;_P 0Z?\ U6+_ ,M3_P"[*/\
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M9_\ !NGT^,7_ '!?_<A42=D5'</^(=/_ *K%_P"6I_\ =E'_ !#I_P#58O\
MRU/_ +LK],J*QYY&G*C\S?\ B'3_ .JQ?^6I_P#=E'_$.G_U6+_RU/\ [LK]
M,J*.>0<J/S-_XAT_^JQ?^6I_]V4?\0Z?_58O_+4_^[*_3*BCGD'*C\S?^(=/
M_JL7_EJ?_=E'_$.G_P!5B_\ +4_^[*_3*BCGD'*C\S?^(=/_ *K%_P"6I_\
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MK^ABL*FYK3V"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%1116)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_Z/2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH ****
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M_L6+'_T2M>P5X_\ \$_?^3(?A5_V+%C_ .B5KV"N0WCL%%%% PHHHH ****
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MS>U?IG_P;I]/C%_W!?\ W(5%3X2H[GZ94445SFP4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4'_)M/Q$_[%G4O
M_266OYU/F]J_HK_:@_Y-I^(G_8LZE_Z2RU_.I\WM6U(SJ!\WM1\WM1\WM1\W
MM6IF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!Z;^Q3_P GD?"7_L<M'_\
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M_P#H]*YCYO:NG^"O_)8_"7_89L__ $>E(#^CZBBBN4Z HHHH **** "BBB@
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MBFNZQ(S,P55&22> * &WEY#IUI+<7$L<-O"ADDDD8*D:@9))/  '.37X&?\
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MT>WT^ZEM+&S:!Y(T"L4+72L5R.,J#["N\_XB /@W_P!"S\3/_!=8_P#R77Y
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M>S0<[/U__P"(@#X-_P#0L_$S_P %UC_\ET?\1 'P;_Z%GXF?^"ZQ_P#DNOR
M^;VH^;VH]F@YV?K_ /\ $0!\&_\ H6?B9_X+K'_Y+H_XB /@W_T+/Q,_\%UC
M_P#)=?D!\WM1\WM1[-!SL_7_ /XB /@W_P!"S\3/_!=8_P#R77LG[&W_  4A
M\#_MP>)M9TKPGI7BO3[C0[5+N=M6MK>%'1FV@*8YI"3GU XK\'/F]J_0O_@W
MH_Y++\1/^P+;_P#H\U,H)(<9.Y^K5%%%9&@4444 %%%% !1110 V658(VDD9
M41 69F. H'4DU^,__!6[_@H6W[4GQ#/@WPK>,?A_X9N"/-C;Y=;NURIG/K$G
M(C'?+/SN4+]#?\%H?^"B'_"%:3=?!_P7?8UC4(MOB6]A?FR@89%HI'_+212"
MY_A0A>2YV_E=\WM6U./5F<Y= ^;VH^;VH^;VH^;VK4S#YO:CYO:CYO:CYO:@
M ^;VH^;VH^;VH^;VH /F]J/F]J/F]JZCX+?!S7OC_P#%#1_"/AFS:]UC6IQ#
M"@^[&.K2.?X41068]@IH ]+_ & ?V*=6_;9^-D&BQ>?9^&M+VW6NZB@_X]8,
M\1H3QYLA!51ST9L$*:_=SP'X%TGX9>#-+\/Z#8PZ;H^CVZ6MI;1#"PQJ, >I
M/<DY))).22:X/]CW]E/0/V._@GIWA'0U6:9?](U._*;9-2NF #RMZ#@*JY.U
M54<\D^I5S2E<VC&P4445)04444 %%%% !7YF_P#!:?\ X)X;A>?&;P78<_?\
M564"?^3RJ/REQ[/_ ,]&K],JAO;*'5+*:WN(8KBWN$:.6*1 R2H1@JP/!!!P
M0>"#51E9W$U<_F@^;VH^;VKZQ_X*I?\ !/N;]C[XH#7/#]O*_P /?$\[&P8
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M!\&_^A9^)G_@NL?_ )+K\@/F]J/F]J/9H.=GZ_\ _$0!\&_^A9^)G_@NL?\
MY+H_XB /@W_T+/Q,_P#!=8__ "77Y ?-[4?-[4>S0<[/U_\ ^(@#X-_]"S\3
M/_!=8_\ R71_Q$ ?!O\ Z%GXF?\ @NL?_DNOR ^;VH^;VH]F@YV?K_\ \1 '
MP;_Z%GXF?^"ZQ_\ DNC_ (B /@W_ -"S\3/_  76/_R77Y ?-[4?-[4>S0<[
M/U__ .(@#X-_]"S\3/\ P76/_P ET?\ $0!\&_\ H6?B9_X+K'_Y+K\@/F]J
M/F]J/9H.=GZ__P#$0!\&_P#H6?B9_P""ZQ_^2Z/^(@#X-_\ 0L_$S_P76/\
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M<G1K9N?*'I*W!<]1]WLQ;QS_ ()+_L#?VM<6?Q6\8V2M:PGS/#EC.F?.<?\
M+XZG^%?^68/4_/QM0G]&J_I#PFX!]E&.>9A'WG_#B^B?VWYO[/9:]5;^-?'[
MQ6^L3GPOE$_<B[5I+[37_+M/LG\?=^[LG<HHHK]\/Y1"BBB@ HHHH **** "
MBBB@ HHHH *X/]I/X#:3^TK\&M:\(:LJK'J46;:XVY:SN%YBF7W5L9 ZJ67H
M37>45SXK"TL31EAZ\>:,DTT^J>C1U8''5\'B(8O#2<:D&I1:W33NG\F?S_\
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MIMW&.6:'?[_>Z^O.9]FQ^T1^Z-%?BG9?\%O?CY:VRI)K'AZY89_>2:-$&/\
MWS@?I27_ /P6[^/EY!MCUGP_:MG.^+1H2WT^;</TH]FQ\Z/VMJ#4M2M]'L);
MJ\N(;6U@4O+-,XCCC4=RQX ^M?A1XL_X*O?M!>,XVCN/B/J5K&V<+86=K9%
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MSI&AEUY%NC9N)1[/(J(#U'DOV:OT:KGJ/6QM%:!1114%!1110 4444 %%%%
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MWM1\WM1\WM0!)9V<VH7<5O;Q23S3N(XXXU+/(Q. H Y))(&!UK]J_P#@E/\
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MFS_]'I7,?-[5U?P(LY-1^.'@VWA7S)KC7;&.-<@;F-P@ R?>D!_1U1117*=
M4444 %%%% !1110 5^7'_!9#]JG_ (61\5+?X=:3<%M%\(R>9J)1OEN;\C&T
M]CY2$KGLSR#L*^ZOVW/VF+?]E;]G[5O$?F1MK$R_8M&@?!\Z[<'8<=U0 NP[
MA".I%?B1J>I7&M:E<7EY-+<W5W*TT\TC%GE=B2S,3R2222?4U^$^,_%7L,/'
M),._>J>]/RC?1?\ ;SU?DNS/ZF^C;P)]9Q<^)L7'W*5XT[]9M>]+_MU.R\V^
ML2O1117\TG]I!1110 5]0?\ !-;]A2;]J7Q[_;VO6[1^!/#\Z_:MV5_M2888
M6RG^[T+D=%('5@1YK^Q_^RGK7[7/Q=MO#VF[K738,3ZMJ)7*:?;YY/N[?=1>
M['G"AF'[3?"[X9:+\&_ 6F>&?#ME'I^CZ1"(;>%>3CJ68]69B2S,>222>M?K
MWA?P$\VK_P!HXZ/^SP>B?VY+I_A77N_=[V_GOQQ\5ED&$>3Y9/\ VNJM6O\
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M ,EC\)?]AFS_ /1Z5S'S>U=/\%?^2Q^$O^PS9_\ H]*0']'U%%%<IT!1110
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M=I'96D"_\LXT4*O/<\<D\DDD\FMBBBN<V"BBB@ HHHH **** "BBB@ HHHH
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M--+^#7PTT+PIHL9ATOP_916-L&.6*HH7<Q[LV"Q/<DFNAKF;N[G0M$%%%%(
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M1W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#^?G_@H'_R>Y\5?^QFOO_1K5Y!\WM7Z(_M4_P#!
M&CXO?&;]I'QQXLTBY\'KI?B+6;F_M1<:C*DHCDD++N41$!L'IDUP/_#ASXW?
M\_?@7_P:2_\ QFNA21CRL^+/F]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\
M.'/C=_S]^!?_  :2_P#QFGS(.5GQ9\WM1\WM7VG_ ,.'/C=_S]^!?_!I+_\
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M/C=_S]^!?_!I+_\ &:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\
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M<K/BSYO:CYO:OM/_ (<.?&[_ )^_ O\ X-)?_C-'_#ASXW?\_?@7_P &DO\
M\9HYD'*SXL^;VH^;VK[3_P"'#GQN_P"?OP+_ .#27_XS1_PX<^-W_/WX%_\
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M(.5GQ9\WM1\WM7VG_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\
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M,4 \J]@G;<P5B/DC;'!YQ]:<=P/Y_P#YO:CYO:OM/_APY\;O^?OP+_X-)?\
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M:ZH_LWZ-O GL,-/B?%Q]ZI>%*_2*?O2_[>:Y5ULGTD%%%%?@I_58445]>?\
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M-\-O#%IHOA_2['1=)L4V6]G9P+##$/95 ')R2>I)).:UJ**S*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &3XI\!Z'XXM_)UK1=)UB'&-E[:1W"XY[.".Y_,U
MYKXE_8 ^"?BQV:\^%O@A6<Y9K;2HK5F//),04YY/U_ 5[!11=@?-&L?\$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/\ >23TJ27V5WA%_*4M=DFRBBBOVT_F8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR;U;;U;;[MA1116QSA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6629032880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Feb. 25, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 25,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $.001 Par Value per Share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>11
<FILENAME>0000939767-20-000034-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-20-000034-xbrl.zip
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MI'H!FSS<0+WK2;;,YB^I?!RO$7GB3AR]6WU1?53_]'/T[C]02P,$%     @
M,H%94($6(#IL00  ;YH# !H   !E>&5L,C Q.3$R,S%E>&AI8FET.3DQ+FAT
M;>U]^U?C.);PS[M_A9;IGE-UCI.*G3?4U%DJ0#>S5<  /=WSTW<46TD\.';:
M#ZC,7__=*\FO)! (<;"#YNQ6D\26=*7[UGU\_I^3R\'MOZY.R22<.N3JMZ_?
MS@?DH/;IT^_-P:=/)[<GY-?;[]](J][0R:U/W< .;<^ESJ=/IQ<'Y& 2AK/#
M3Y\>'A[J#\VZYX\_W5Y_PJ%:GQS/"UC="JV#+__]&;_Z\M__]7G"J 7__:_/
M_U.KD1//C*;,#8GI,QHRBT2![8[)[Q8+[HA.:K7DR8$WF_OV>!(2HV$TR.^>
M?V??T_B)T X=]B4>[?,G\1EF^R2G^SSTK/F7SY9]3X)P[K"_'8P\-ZR-Z-1V
MYH>W]I0%Y((]D&MO2MTC_EM@_X<=ZHU9>(3+AS>_?*;$I5-X-VBVC*^]5J_?
MZ+5[[<9@T&^W.J>M[K'>:O=..F>#@R^?/U'X?_Y6_$\\LV.[K#9A",RA;C1^
M/II1RP*P:T,O#+WI86/V(_DJ]&;\<\A^A#7JV&/W\-]1$-JCN?C*=BT F#^R
MM.CLG/%X#AN%Z8"9M[.+<CU_2IW<&G1\!H8,Z=!AQ&2.(W_]VT'C@'\.9M2,
M/[]\BQ]L*YP<]COU?J-M&$:KV=6;W6;SYZ.AYUO,KYF>X]!9P [C/[([@D#Q
MQ?GP_Q:!1V Q[M\.FG@,H87_^,FO<FUBPF;KYZ/XH<7?C/[COS6[Z6\K!K]G
M?FB;U)'K$^=ZE#L#8^&0LY\E'F2_XJC/O\F?JP=3C1SOX7!B6W"61_($C=4(
M@=^L.AS;G3#?#I??^.M?]$[CZ/,G_"%&YX4-4;#N$ZP<F3]Q*D^^?S;_XHS"
MR',K3IM99M/M]'(P])\&80###'U;"T#PU * 9K3P+E"[YQ_^931JP/_$;P]B
M;4//L1)8E_]=@#YEU4-_ZT!+[FE/QR3PS;\=L!_ ,;VQI_?^;%*]4?_W;'Q
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M\IS2P@E8TRX30GVJV'(U0%ICTSX52;#@N$.\6?!;I2%]U\)0V_>M6P@M^1
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MCTOF:#K<+#SX\D'_^/D3C+#H_RD/Y2C.41K.L9S7V,EIV6VE96]A5W?7(;4
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MNO,9T#$V-Q(>S8#<S*<S+["C:9:/3YC#+_%OJ"N"<L$>\#2":QYYOFM3+@
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M%#:)5PS*[#M6$<N&Q&1*%\:!A0%Z[GEQ: ""1Q;R>=#@\]RT1BWPNCMQSK$
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MG_[,^*3H*F3C-Z1<5/NBH!X,T7QJ"&,97V-8Q3#<&YH%G6L%>D\)JI*#]*J
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M(F27WT_)[26YN+RH+7Y=%9@7(KTTPGZ8;!:FR>>$3D'+#%4,V"HXEME7A:+
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MVJMZFCDT!*(,O<5^9D$T#(#P0ILZSAS[F3W5Y(R.J>T&(?\=*9^Z<TXDW:.
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M3%=)X^:*1H1J/Q&RO@JB%P478Q0&^L+POD(!0G@@2($)(H\%J24\V)C^YV=
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MX7F>A >JIO1-37(U\''8QB8VP31JBL(YOUH/_&<V;KL<]G/)">RZI_5MBO$
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MENLZ)P#P W^<3#9J_\EDL@%8\<-T657KU9K.ULKZKR/9!> G7-'X?[!E\ (
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M.1#B:FX7X@RD,[5*RY(/Y#/UN,OF"NA<W2[C2@ I-Y08[ O 5B,4=U:#?L9
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M%Q,>1SEM=8I%&NKM,4IX0;1&82SC]$E^V>DJ>W2)0UU!RA^3&C%WTAJVY4&
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M2CFJ5B@!*,UH2$LE&Q4A+$02UIP7I_-VK-PH%6*ZI54,B?6L1RKD4ZJME-!
M3&?<C1;M\V&%<,6PH60U+?O8NM@00XXD"FP!%/$E@Y);HH8W+; N!%E,#^N
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M3AD:ODS UX'1@B5VH_/5T>2PHH\$^'ZG'C>G[_$SU?3>DD5$X_'PV5Q7%<S
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MV+E=']9Z]J.D(917IM78]1LT/2;PH@/EKV$B:X,,,( EH$B','ZHV8^4]TR
MY1-X=GE?P+%JK';$H8;46"?VG@E+N-[7M;SP82I.H )U<$;JH WR12>,<Q9*
MM!KS+<W[.F*/U.C:WHD[ZE26U@[;>)I3M?V@C GL0U7?@]JU\ZJY,(&:)X,V
M7=:;[MN6PZI/PS%3\0W[&D<7O9]J24'.:KQ/*M^LPA:DUC"!H,R@3XA+1.<,
M^8E#%S.J[&:^6(^4(X4+O#B_N35-"@;V?;[W]Q+5OS?/B,;V(2E"W&(]*\VD
M4JYK_7V2LFAPWAVKIKU-0GMK=?P:6V_)J6LBBB;D*"JL!&2D1^?#2F[2E]RT
M?OEKL>3(;QMWFMKF>DVQJ8HM_9803P,8VDN?=EP8?PIC#"]GG6#W1HU[B!6]
M;52/>;MCA79Y&X=%[ %A)87&1?^$^933C; \&)%QYU#ZO:R&1R+/U'DLL:Z+
M7DZFXE"#Z)B0MY#+(,43_@^G!ZLI<:3+M6.L:GR>XW+<#F1SP9#4[+GE9;2#
MW">!@8@+7]G/X'=ZI&N<I%WHTN#Q.&9,$JOP%D0GSQ:VN[F[B&MW7M47:)X%
M?J:R%"FF5$_D2*4(O1 IH>?CJ5@?\7)]R\S5\@AT>2EY<I\-2\#;0.GA"=6K
MW&QI#9,M)AH8>AH67^G>/3ILC]Z'@!ZH^!KE9]&7/"9=3I_-JMZAQ;_G4IU?
MRRG,Z_*?/.X898ZT<R-;KE*"4CKRMLBI6^[&.[_90L;M1H*5S)JWP9JWR?PI
M_C7Y;A2AH/(LJM.<\I8)^.MM,@&!9,8QBPEQ.@\F"$VY-88B#:[)O1^,>#_X
M\75V.VBS 7V49B:@Z3ANQ^!1'J,]BZ XP4/1ZR:58BB"D0\3:'1LK80[:, =
MI'T7U\?^_.'#OPY0_GV:G#Q-3FJ2_9_A_WL-7SD/NA0OPH/46#\6(GB^B&07
M2C,=#_%6%]MW(L2D=UG.D%7^;FZ0@&^42M,,SU;DFK?I+(QVK),)B,:-B]-?
M.#&!=<^TCYDJ14\W'((E,@_XIB^4JB%/=LI)B\4N'\'<\Q#4M0@L2CC=<O&4
MT*'96K6SKR]6[SIL*O&)HVYE*'=E8G/1F%2Y4%LTQEMYRG+6O2P[7UV;\H[J
MM%'HQ35MW7;=WVWQ,7+AE,89)G @BQ3-",;5M=,DX5C*$G*$,8C.%?.G/J!Q
M5A(K,X4+>H3;?D2F+;:^<^N 2'F]@9<NC.C?YXZHC@B!L&V,^<(.%Z#8/*(:
M]*#F'<M'!^=Y)VV>\.M?O6K(?_MQ2U7X :<];]]DA^?]V3>@?W$?S-FMBK2M
MB@Q=(>?_\R-SF'Y!]:(](HYL#UL@3$BT*+F+;EG#E@TH/&>>W)R5WB^>;&##
M9S<$8X'BRZ"\&A#+6HY0&5>XH/W7"Z^_L_5;3=#?WML)I<Z+B>.RD"'(IC&B
M@5P ME S=XCB?LL'6J<CN)4OHRVM_!7XKG"7,S=MYHW("]_J)[N1K+317KLK
M.#F$?*;Y_%&WD39_^IL0Q8KZ\H!S=]W.[<\LEKRX?"X]1J'A<R==U@!V  Q6
MDEA\^@&JKA;?<X2W"YPC/.L>&$I\R$JRV*.G9"+#,LZ_B-K#$OIZ3Y?4\K7J
MC(=.Q:"N?OZ/TP;E&>0&>J8K1_\$/C9QO.UA5GU56V5<:N"06*KKQ5.'U @>
MTFU^!1=5Q('G'C,T'FL&VV&^Q3!B$\6]UMV@J [*=>&[?7Z D^#PE/E2X&;I
MJVK\-YFF2QR33("F5-2@ORT%XX(2TRN9P$1!*\*&4HVA>5'>9E"*ZG!9/EF.
M1F]3HX_<6DSSHQC<VFTL /"T@AO2>>1SJ*W8?^A@,TY:)KS_BX%"B(-C_-#9
M+,1U,"I_H3*!<-Q;Q&@/>)GM'IC#_N73SK^,X!G7MJ35MJ3Y^N\-;]Z!=8P(
MUY#H6UP?41X/K-==NGSSK4Q6%IXD0VU6"Z\VYKGR5EH'V-'S;A6$=JPQ%!\*
M(=X@X)UXN\<WPZ2AXV[IE[&USXQ2E926H1-++YA ;-2I+?5#,U$3CUJ:[[B4
M::317S)V4O+P6M7LM]7<QU<X/6H;S N'*FXXF9HF,%1YA:<* UN?L:4=Y(];
M*=372_3Y$BSUH?_W?- $=.@R@UT1#QNH-2@G,H&7^(C&!,D":^[Q?;2*\S47
M7YOH/->P3I^/]%4Y41H9O JA2$-IW UKM8.QR<3 *KZ&43=]\;K2K#(&2?G@
MHZ1['7@&*5!85:4VF%8'>M]MH\K,'X:S$5^0TJ!=6B'5$":5,7'U2X3WRO>;
M[1,M1),T$VKTWUE3FAQ;F< _=&*K6UKRZLK_LM.GY;+G_0<B:LB)LO\9_+_]
MX&-,P XZQ#H^6D*]Y'&P97,\KL[QNVK[87NB_BZ&2'G4J0G'^-[(-TV73^WR
MW5N]!^N9L=5#C\-.3B$%F$!_&TCBYVX9TWGZ% ^<\N<V,(O]-R5B!:$BD(/G
M]1=UB9?@A^YH'2!7I)_)[U28\<$Z%C?H*IU;3=XE?YC1,LG+[;RG<<F":D]A
M):L0DQPT3O<JC5I*'1.0[-D'7VEB3'H>L:KO_[KS@K@(RU8R]0)H\FZ,4X@K
MV.(BHGKV>[RZ2%3.^;JX03\,U?#:ES-HS5">]E&5/967*04D]SJ4@)I/F@>Z
MWCRK+R?+ 5[I&/3^TV+P>2$)@O$%MCT SP_$:&^Y?4I)2+1=AB.D"-Z0]60C
M6XR20V([=RRM"+?LU)T.?:)LO#)'\S?YAQ0C8^K2?W3C9YG  !^YE)(S#AO$
M$@+>IR/T*8%I]MN!(:X9CAD6Z,.CN@=:]3TYRYW#3IJ8&%XTW'OBM>.F.38!
MU9_*T!<FR-'#S:&,N,NPCGIKHZ?:C\!-?W#[7RF--8UD]*(+QVK!XYNI=?2>
M.&#AM%'#E]OE!+QC4"'#$2=VMQ\;_CH3.A,\@<(GHXK([ZD<B--!61-^1J3L
M<HQ@6&K)%M=QQ=;^F99+6OR[^_V/['B+.JPABM#%59[V&+M)$@\JT*VP-N\5
M/3L\<D=CYFG_P99/=W<#DL\! )#2KMG.M96"V"!0(/M:IMT@T8?[&*S=Z]B=
M<V]M=:X[HI 37W2;*LU)/WC5?)$D/.['.R:PM$#*JXM;<GE*LF@D-8UH9A>Y
MV!]A L^OM&!3/)5_"1063Y)E'WC!_QSZ\E&UC@@;)I!40)('1>?[%8:JE>WO
MO *TWK]\;,E:(S<D/$Y.(<%JR)L0'@V1.Q;##GV1W[DK12ML(J\WL7T[>]?W
M[%ZUN[@@T'2Z:3Q,(*J1($?=/\ $9M=_DLW9[6");*/'/]-DF# 4/LN*G?*"
MT+YK@':%*!>J9ILT-#LOXY8%O=XGZT0XG8=<GM0ZYK_;K+"D\>1K(O<[JB3(
M(P700>L6;<HWBP)6&QA\A<6^QL/15^>-8P(?7Q0F8?A>Y;J]L]TX?>>'K*Z.
M6'=H;+N^.L[8U4=NKPMWKMI@N&W3UZL<HR$ZZ9ISHEF]2WFSB]N0 !01A^*%
MSJ8AKH!1-WP-C+H&8&!U)UDS@@/K]&D2*U#*E!-R")V[-+.()DT8$K?,/G<Z
MH[H5O%,A"TNW/WY*6 Z4&%U(")5J<J1DG*Z;+I:^3HQ_EQ>*'W1\9X%)&$$;
MIS-BIE34 L]6&S;B9XUBSD<:ADR&MT\E6RAVSK:#MPTHH^2 WG-Y7)S![8ZF
M/8F@.&)#(.NW-(10!"U/D%5(_9C-ABZ%HFA, ,W8+;>FSK&!DF("GQQ0E%VH
MIG7]/_^]Q%_'+%\.AA:"E'F-@:)P8UNAO30,XT4Z$\ ?9@+"79G81Q$AYCY5
M4="@48T' BFX[!08=>I#1%>%+@%%XVF<4*Y=B*\GY]P;SU 0/NU0^/ V!J'#
MV]A>QMN8. <[TVD9KR'>1LR;J1UWT 39W] TQFY-"QW_6)]C(IVJ9L7V)NZ#
ML-ML5^F6 K*(\7V,:((.!-T^.RL??4C* U*GO$O$9?2Z2$Z)==4^#<#01\1X
M'I!VG*\:BA-^[;@UB<G'XC]"B$:6EPD',:D4\49<%\SC$B%VM-W@XZ9N$M?S
MQ'CZ NJFY\4FO!-FR$.\89])QG%>;R=78\Y<[&9?"Q-HS8PS=LS;BJMK3ZX[
MO2[^EE@Q&#:<5N3N7-E688F--84G5R0Q <.T-,);YY-FPK:N;OM#4R6KUD_T
MQ-!WH43\_U<V%"+,&!HC7EOA8'2:\B%%B:&QE?RD-\^;SW(/67_%&MJRR1\/
M9'A)G&.(BBQ#WF+Y&8!'+1E!DK+7.-T!S_?.1)^:TNNX\X)F<.ULE%QI=#A%
MS73%V)925%VJ%9%_RK7BJ6[WQD>E";I3UE)I.SO=^ 7/ECZ?AT'<@^Y8J;WT
M,+L,>ZNS2)>NMDVK+"4DB< $(LP:.;K#62&03,)$DMZ@BV6RC'.<=K-&D$KR
MUF82UHPA T:%8Y7<B OO'#\>*,"PCF@_X6V8:"]H1S1*6$?8NK% _3U@P2C\
M2X90P5ML#O+$PZ+.F8@B^]7!0G6R IJ.<J 9G2;&O2)VY9^2#"FWP9YZ@JUB
MQ+6HH?##C[A JF1+RWN)54G7(FGL3ZKL\F/L=2&=RQZP(4%?\ [;.6;5#ZEZ
MV2*>LTZ[K%C&^8'W*<K]?HSB-RZ0>284'GBC:_#2:/6H9B/R&23%LT=-?MP\
M=RJ<!V/*L]4L6"G5D,V6*&AO/0["$7\SX[#=S(C7RF(O]3#B$CV]0 )%$.C\
M[*=E-Z24Y[5?Z?0+'$=H4RTU)T M%/\4EH+=@\*_80*LR$-W:MUD0US&*RX=
MYT'?B;]S KI1?ZGN*JH\5"O+A]_.]N![.YZ*<@.+H9I$H7 %ML@T/, *<%R$
M)8'\U%?Q0\R=Z:\&#&V'L<QWN5OB\Q&-E+(YY<!0@8/'/TW);6T972GOX7+:
M>JJR]<4C8M&=NLL#2K[06;[ S1@D:;8\*NO+MMYIJ/I9MRD8>E<'6M?((CBG
MR4-E6,02GM#4'A>K2%Q2%:4[C)EL^.A/#L^<;WS07S*1=S0[Q0PNOB4;)!MD
M)IIT49/;U&7J-Q/<C70!C]0<"D<OA;QO]]<X ,*YIG\H4KC2'XM380)QBM 1
M0ZB'EN%.&X!0$<)@0U&],(MSA#U$E/\RCL$5]F1_LX*=^-5"9[7:.:G0EP):
MTBZKRS1TU-6$J^X/'EC'WG^BLZ%(@80<]UE,EHZ0BRM?3Q?M1 FMH1QSNS.*
M-@*?:W![>]8&RWMX1[HG\_5BMCQPMF15K+=-]J!$$O9]^^+SI. %!@N-OQ?U
M4"[D'>2EJQL3N-[G?.7JI938P3.M4850_T/RD-1TGD((AV'%[<XDS"F%*(O"
MD:ASI/A2%7.NNG&1Y+WBIY1S=2R+9B- UP^!Y:+) 1G>)-CM(GI;I _T@BG$
MZQ);^V-PI=:LKW6;.](PG:75%&OBC"Y%$SPV+>*/((Z!]8J#O3(RW27&1X8;
MR\Y\/[.LH[[@A2U6@0;:3[ZU5-NO(9J)]E0?FRV/@K;"#E$:BKCL8O*NQ=V$
MQ^ZCQ\OY>V&#F(#GMZ1@J;F(H-^S@:OHP??D#@J**DBYY\;![\A^H+>&-[=K
MZ<([!A,XCEQ6BXA3@]]/X]B=>T'-G<8-(Q.[H?<Y7MZ?Y_&[28HM%A3@T$?>
M^M:P$'3AQ);!Y..#9L%I#69Q));QB'K]PP@'4MMFD)I1AN6">=]GZDQI\:.<
M=6,6_YLJ;)\D7SP',D+A&6*&.633)58FL'N<$C-1]CT$ML.^%/9BO3R2IRY2
MAO&IMB??K^5.>,W9BPSAODH7$NO2$D@2<-/3$^-%$1.1I2%ZSN-=4.JXF#%=
MJEGC%ZTZH"G\'^,(1G^??6?[$?B6(DG>AA0,P=L[(AC-*2NSK.BH/14,XQS-
MU?YBL_LV_^F+_+L$3SO6@2IYCL'&!)JMB7'T@$=,8-WK)_-8]P&-_53QW^=H
MB$"J':KZG@8$V9IK.9L@\)#F-K'7_2JY\.D+Z[L3PIMKH;Y5&V%GAP]=>_RP
MH&8&QV=JT#^DH]"EM?]THJ<(J$H_V43I SM^Z"%RJ&#4K;Y?N9_&ZKFX6.!9
M[I)Y.88J^W)71P:JX+%V"/_"MQ+("*8%,^A-WJ8D4BU@VFK&X_S)7>S.(5>[
MUYQ2Z^>HWYZ>%'AW:5$>5^"! WG65?1398W&8>@Q%+X<Q:/V;,V" M7K*.>P
M:464F,@ML4]9594GM]"26-47IO2#T?FI=1QA:ZH>10U($=).5>=5N-RDMZLZ
M\G9>CE9N&D\=[6=6H#<IV.)P:^TO5/K7Z\N)7XGRKQ?PSSH9N11'JJ8'%3_Y
M=92'A ZB:61$C/3/&]9R3>2=<,I4?R54//:+.'H-N4<3!K$.3W.F>) :LRP?
M(A7R#%ED4^]_:^7KM/'[/C-2ZW/ !T8T8K#/$&<:Y Y@P\I5LRFR!(IC_-Z>
MQ>[A-^P2&U5!E9782*QR 42Y0#_O>HH8ZBH3V*>A3I&;^!%&3\2/<3^L%"XT
M/B#>GQVK<Z+]HI =PFZ@2A%GNF9$B."93]B+D]G0XS/L4?AXH[?HLKOM8_):
MG8]Q1X#1NB)9?[$;M/<&RD?B6WP.*5,)>\C5]N3UZ$C']"OEKF]-'2>B@P[E
M0!NDSADM&J8/T\.2RK7(YN"*7M+DZ-E.22&UYVG/2B=DYQ3T='D'?5VB"_8)
MW52-?UNUK'6-/-_:\<?\$[^OK#[@IA&S%0+>$>32OC]&#ERC5D-9Y6+WWI6!
MH\8]&FPBJT]&=:OMAJP-13U=M=[1#C*NW67TXFPDMX?L& $6X#PX9D'22R_N
M<Q:"O^NK#C+8J_[N_C'UO9K0L3WERHQ]QYC KI9"RH8HMJX=8KXU>CBO6%BG
M:Q(69QXK'Q"E?_OPBV.HJ>2='"V?-2*#==]&BZW8>*PLEH#_U4<IH#I;*K^*
M5>I:5[]D+3UZ O<YFJX2'>M1O4>G_P.M=DK<%S]=V4MQ9P)[: C5+FEA#0E2
M7$C!]UX(M'_749^RXRBW*-,).JF;F+W"8-,'9R[:@[V;Y5BK ?F9CW'-,M=[
M4*/[:KJTY&%B_NW^JVE"FOP0+<'X%=CQ>29 A,F%;FZJ9N6C LEG=CY+LL?)
MNB2<-<>OJG]3_UHQDZ,Q/[P=5P<C7L#X#<;XR:*S/=;T2EDFHY?ZUL10@R9^
M(C[\7AN86*C]&.4DMB["CZQ\--5WQ8EQTO[FSA4X?%]ASX1!^R'>>[*LM+4G
MBUZB.I] -T54GK7'+8B20_#J5\>2ZQ[)"CU"Y7Z'LL[O)6,*L/<@%"F.E]!'
M8;8(99_49CP3.'J6-Z#&\85Z91(WY^B5,E-I0-K@S:'S?-4GO9O4^Q LU(/@
MH+=H;E3!A0[*TWIQ0Y*R;]8D56'0=@A2.'=,AW5QD9;=W2>NZE'5K^- #Z48
MDTQ!57@,L>,+!5U[-*8R*\FA<Y_3LI#:X8Z,@U_GG_!K[]8^\5P3D0KNIC9H
M,C;VV'S<2[ER>_R(QC'HJ^U'8G;A/'LK3X9IG=&&SA0;K$*-GH=5F^B'@NS[
M-:20/K.(([5 =E("EK7+^2;8$QU%GD;QZ6(?B3S=3^]H>S4Y>]HX8GA*5<>2
MX]9B^\!7B:0\Z?](%18-!\Z)CNR6MR^%!R"YYXH.')W?1R_)DH1@CY;H/@Q7
MY=.YD[X<>916 X+&;#M%2CDTE82A<;.,[X_F/3RW>=J^(Y&Q*V!41&7[VP,F
M\.+9'.S<SZ3H@5#;XE^3E[]<O3:!ORC.7Z\+K/\=.K!$%!&N18N%O4*3=Q<Q
M@<YIK#H8\.@0)N#GH::Q1FD<#\C*H959J&MT0(G1PC\FO=$C'*GCDI*/;KE#
M#=*2@F>4?@G[%-!9VD '7-<?+"/@:*()?'FLXWP!3NUO(B/>FQ7P6SO[V-S)
MN^JC QO?C:Q+>O?,_4#[M//M=_O,!,P$CF1([><13A/NBYXF8SJQ%!EQ&E<M
MXW#6M;4)/C]IU#C,1XP)< U<0)-6Y"$4^DVH?_/.ZZ[691];M6;$VY8LS\3T
MMA[]]H>M[JF#_(*SOU[ WW0LB;@@-XX]E(!&DRZ,K )=5^^CK)/SW2>Y%X4.
MM;1H7=J[!_L4A7_/!(J<T=1'B*-FR^]&<0V#;%F5)?>+;[9%Q$XK,H$$P[LD
MFC2_YPXS[#XDW&$=,N!-CB9Q+":2XG1)<8&B3$ GQRE.*;/N<II%CJ -)RJW
MRJWAEO^])AZNL$Z#F(C9J.!QE%U$Q*@@_0OC\$/&66);^\<O\YVVR0C/OJ<'
M17POTF3#7GL+[A75%B_,?GKW'U720!HKU;HTCGC(&Y$.5J#VO$U^2%YR<W<[
M4U-_-#1Z7O_N'AT18-\)4P)D:8/JX#!6V-@PL-'<YP@].)>2Y2ISKIWF-32S
M4KPK0NGZGB?[&MGVL4D-0_'?H$0#".4A_*@><:UZ<XC&0:"&6HU<8@)E?<L=
M"1>/*QP&3_>T7%._5NV8<H'3#:6>'X:S?]QCAP?_>/M__\T;LJA*%7"$%:(;
MAF 'YJ9UU<5P?.=_I.1)W7/ZP*G*#UE.VE1;WW^IG\,1=$\P5E:K#9$_49Y7
M*I*,$U8 R@/\?7[3J;YLW/Z3U?BZ#_RJQU_.2&LM?A6J"_Z::'P58'DNQ4%
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M@R4R]7YCRFR#E9&.XP)B\S7;@^S?C\U:C8Z/NG)JJCFSY9Y-X-<6.>1Q D<
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M,*R=D=[E>O%$/UKB_.6D39YC/49*4?A.@,K]"#/H(10  NHH/Q2'50R2-;\
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M*8NFVI9VV<G,0VQ+*B*U)/@:DUV^WMI$I?NVZ.0X7?<"8/[E]SX:O]2O]OQ
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M[GP!\EL6 S3Z"MFHB%PWQ:ST,D!+;33IE%AEOVAP'(;(AJ(92U%+()3"<'(
ME)[#33='T89@[PSU.X]]TYIV_MGS4NG'>QB@["; P -_]329B^9T^WA>?Q-
MM(-S#%#?'0:HW8 !JCKU\X=';UEK\*^P&2+N :+_W6M )@0@6[FP37ODAC4B
M3E_K%Z^$LF. ]BQ<BMT_0[6,U,:\L"*4:T(N.GV&",'2UWY\P6;L;B0N +D'
MP0-3]\F7K)@,+A_\(=RP_)"Y.--+>.;%)<'DH=XMDP%+7D)M JYFS\#EKC6*
MA*AN 51RK/OS[J=[N?/[-$"G%KYXY:Q=?^#\(&^[F\$?)G*8S*"H1]SH+$(
MQE T*LGJN*K%RNFLO;!#EA\8(#G_JA!:M+:RS@E4 B5S<)X!DJH!;,YEC/-^
MJ<$,W()<2,R&X#GB3F7%DZF/ZT^<<\CBID1,W0)7-[(E!%+E!]8IRUP.L?'O
MTCU<?3/G96HZ^CXMW8V9,+GS&=\2V?1"."FM_]6DK]GAV(O?)U'>B/OGYGB
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M]P/_"$_RSP<%"ONM.AK$[W3<%60MN?V=N)UICOW7&!1+,R;@\>W+P" (0=2
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M0@4,UUAM]G?6-XC(U)7->[YAHVRKK+^'+:_R^Z72D,%Z.=GOYZX26DJS!A=
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MT,3J4#UF+!XK?ER3$NU7>='!]%DBN.R.0@L_%6"CL=CY3(^'&=(QV[X,H06
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M!(98NITV--LK!6;0YB%K"GIN[^ZVXFPWA;^J>GLZM0HO;PONY>4/:N^1;J2
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M%GO]/'S04__?2F:D8J@ ^@7X"86[YBES/OYCN;3(C4',0<S\LJ9\\K/[;A2
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M%1!RW,^1"H"C]E$!F"X(15*-=-4-ZTDB$_<R2#%4 #[!KT76$&_UDPY ;*B
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MC5=/>IV(E2K]^@Y1?+<G9/],S-D.?L";_;/SU36">YDO"T0B%6"#( J :ZF
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M73Y=0 58$87J=I"A@GJ,HG&XR;&19)BOY*.K-,-D+PGY./[9B73"6+LSN=^
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MS+!BORS<Q1JQ[>K^Y,$-                  #XI[,UB?\'4$L! A0#%
M  @ ,H%94&_OCK%0 P  YA$  !$              ( !     &5X96PM,C R
M,# R,C4N>'-D4$L! A0#%     @ ,H%94&!?4SXX 0  ; (  !4
M     ( !?P,  &5X96PM,C R,# R,C5?8V%L+GAM;%!+ 0(4 Q0    ( #*!
M65"PP\>+G $  +X%   5              "  >H$  !E>&5L+3(P,C P,C(U
M7V1E9BYX;6Q02P$"% ,4    "  R@5E0O--$"(@)   >9@  %0
M    @ &Y!@  97AE;"TR,#(P,#(R-5]L86(N>&UL4$L! A0#%     @ ,H%9
M4"HT^SA6!@  "#4  !4              ( !=!   &5X96PM,C R,# R,C5?
M<')E+GAM;%!+ 0(4 Q0    ( #*!65"!%B Z;$$  &^: P :
M  "  ?T6  !E>&5L,C Q.3$R,S%E>&AI8FET.3DQ+FAT;5!+ 0(4 Q0    (
M #*!65 A^M ,.QH  #;&   :              "  :%8  !E>&5L."UK<30R
M,#$Y96%R;FEN9W-R+FAT;5!+ 0(4 Q0    ( #*!65!AT2J161$! ,+& 0 3
M              "  11S  !E>&5L;&]G;S$X<3-A,3 N:G!G4$L%!@     (
-  @ ' (  )Z$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exel8-kq42019earningsr.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "exel-20200225_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exel-20200225_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "exel8-kq42019earningsr.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20200225_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20200225_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "exel-20200225.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "exel",
   "nsuri": "http://www.exelicis.com/20200225",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel8-kq42019earningsr.htm",
      "contextRef": "D2020Q1FilingDateFeb25",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://www.exelicis.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel8-kq42019earningsr.htm",
      "contextRef": "D2020Q1FilingDateFeb25",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelicis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="exel8-kq42019earningsr.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelicis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="exel8-kq42019earningsr.htm">exel8-kq42019earningsr.htm</File>
    <File>exel-20200225.xsd</File>
    <File>exel-20200225_cal.xml</File>
    <File>exel-20200225_def.xml</File>
    <File>exel-20200225_lab.xml</File>
    <File>exel-20200225_pre.xml</File>
    <File>exel20191231exhibit991.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exellogo18q3a10.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M'WY78=];MW?_V/@BJ%KX=1?J"U!+ P04    "  R@5E0F5R<(Q &  "<)P
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M(9+CR^^9]9@\4_-NSG;2O0KWS"Q>F=E'F1;)PY:9$(<101<(,B,24WL6H*@
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MVE(#P,&7U&@$^\;H8KWWN]+(+SH(L>J\^I%07L\';SV,&QB02RJSM 6,20W
M;KP]2_#0#28A3#,*BNQ&CB>65H*2ZA,O>43H6\>"/4E<J*_WL)\)VV$]=N'?
M(*EA.N_6_VATF<N@7?S-R$=*[4%?#?_)\@M02P$"% ,4    "  R@5E0'R//
M \     3 @  "P              @ $     7W)E;',O+G)E;'-02P$"% ,4
M    "  R@5E0)^B'#H(   "Q    $               @ 'I    9&]C4')O
M<',O87!P+GAM;%!+ 0(4 Q0    ( #*!65#;OE1L[@   "L"   1
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M+GAM;%!+ 0(4 Q0    ( #*!65"ZH3F*UP$  #(&   -              "
M 4<.  !X;"]S='EL97,N>&UL4$L! A0#%     @ ,H%94"UMI6@Z 0  )P(
M  \              ( !21   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M #*!65#_P"8(O0   (4"   :              "  ; 1  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( #*!65 +C]@#(0$  %<$   3
M              "  :42  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     *
-  H @ (  /<3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>exel8-kq42019earningsr_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="exel-20200225.xsd" xlink:type="simple"/>
    <context id="D2020Q1FilingDateFeb25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-02-25</startDate>
            <endDate>2020-02-25</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="D2020Q1FilingDateFeb25"
      id="Fact-7B9A8A67D8965AA3B7AF0AB2FDB0B173-wk-Fact-7B9A8A67D8965AA3B7AF0AB2FDB0B173">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="D2020Q1FilingDateFeb25"
      id="Fact-350BBFF49FE45D429976426DFD564A84-wk-Fact-350BBFF49FE45D429976426DFD564A84">0000939767</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="D2020Q1FilingDateFeb25"
      id="d41425420e96-wk-Fact-489A86B29C7D5C4D9885A13070C6BD7C">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="D2020Q1FilingDateFeb25"
      id="d41425420e110-wk-Fact-D29E5DFF7F7D591881758F515B1606B3">2020-02-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="D2020Q1FilingDateFeb25"
      id="d41425420e129-wk-Fact-13838CE6DFF65CC492941BD05CFB4055">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="D2020Q1FilingDateFeb25"
      id="d41425420e153-wk-Fact-C070CDB2083E59F59954A312C8D78EBB">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="D2020Q1FilingDateFeb25"
      id="d41425420e158-wk-Fact-3B3DE49764055A11BF94785A1942F3E1">000-30235</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="D2020Q1FilingDateFeb25"
      id="d41425420e163-wk-Fact-08496EF451965B6BA76E7CCBC1E1AA10">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="D2020Q1FilingDateFeb25"
      id="d41425420e185-wk-Fact-41CB20C1D5375A6D80777630DBA4D259">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="D2020Q1FilingDateFeb25"
      id="d41425420e191-wk-Fact-683D139325D35DD5A3466446B3962EEB">Alameda</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="D2020Q1FilingDateFeb25"
      id="d41425420e196-wk-Fact-18F1E2566E4759D2AAE6CE184BC1ACF6">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="D2020Q1FilingDateFeb25"
      id="d41425420e201-wk-Fact-6C42445B3A4E5F319B6972E519DD65B5">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="D2020Q1FilingDateFeb25"
      id="d41425420e214-wk-Fact-90A806F7734E5497B541D216472F0B42">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="D2020Q1FilingDateFeb25"
      id="d41425420e219-wk-Fact-DC393A97DCA9514B8B38B8724096377B">837-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="D2020Q1FilingDateFeb25"
      id="d41425420e231-wk-Fact-0415EBE197885348BCAD134A532E744B">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="D2020Q1FilingDateFeb25"
      id="d41425420e239-wk-Fact-095D4C1D8DD85073935F4B37A7FE8DAB">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="D2020Q1FilingDateFeb25"
      id="d41425420e247-wk-Fact-CFBA24DE466F52DDB4A67DA71D8272C9">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="D2020Q1FilingDateFeb25"
      id="d41425420e256-wk-Fact-911BCF8B9EB454099B4EBCF71784ABBF">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="D2020Q1FilingDateFeb25"
      id="d41425420e298-wk-Fact-109F18A8A2E059EABE57899D254F1687">Common Stock $.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="D2020Q1FilingDateFeb25"
      id="d41425420e303-wk-Fact-9D247C10CBB958F990AA22A36FC540CB">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="D2020Q1FilingDateFeb25"
      id="d41425420e308-wk-Fact-C016873BF1AC5245AEB6D3228CEF854D">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="D2020Q1FilingDateFeb25"
      id="d41425420e317-wk-Fact-8FFF01B4536950E58A81C191922A5331">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
